Bausch Health Companies Inc. (BHC) 2016 Q4 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

    Operator

  • Good morning, my name is Chris and I will be your conference operator today. At this time, I would like to welcome everyone to the Valeant fourth-quarter and full-year 2016 financial results conference call.

    各位早安,我叫 Chris,今天將擔任本次電話會議的接線員。此刻,我謹代表公司歡迎各位參加 Valeant 2016 年第四季及全年財務業績電話會議。

  • (Operator Instructions)

    (接線員指示)

  • Elif McDonald, Director of Investor Relations for Valeant Pharmaceuticals, you may begin your conference.

    Valeant 製藥公司投資人關係總監 Elif McDonald,您可以開始會議。

  • - Director of IR

    - Director of IR

  • Thank you, Chris. Good morning, everyone. Welcome to Valeant Pharmaceuticals' fourth-quarter and full-year 2016 financial results conference call. Participating on today's call, our Chairman and Chief Executive Officer, Mr. Joe Papa and Chief Financial Officer, Mr. Paul Herendeen. In addition to the slide webcast, a copy of today's slide presentation and a replay of this conference call will be available on our website under the Investor Relations section.

    謝謝你,Chris。各位早安。歡迎參加 Valeant 製藥公司 2016 年第四季及全年財務業績電話會議。今天與會者包括本公司董事長兼執行長 Joe Papa 先生,以及財務長 Paul Herendeen 先生。除投影片網路直播外,今日投影片簡報的副本以及本次電話會議的重播,將可於我們網站「投資人關係」專區取得。

  • Before we begin, we would like to remind you that our presentation today contains forward-looking information. We would ask that you take a moment to read the forward-looking statement legend at the beginning of our presentation as it contains important information.

    在開始之前,我們提醒各位,今天的簡報包含前瞻性資訊。請各位花一點時間閱讀簡報開頭的前瞻性聲明說明,當中包含重要資訊。

  • In addition, this presentation contains non-GAAP financial measures. For more information about these measures, please refer to slide 2 of the presentation. Non-GAAP reconciliations can be found in the appendix to the presentation posted on our website.

    此外,本簡報包含非 GAAP 財務衡量指標。關於這些指標的更多資訊,請參閱簡報第 2 頁。非 GAAP 的調節表可在我們網站所發布簡報的附錄中找到。

  • Finally, the financial guidance in this presentation is effective as of today only. It is our policy not to update or affirm guidance except as required by law. With that, it is my pleasure to turn the call over to Joe.

    最後,本簡報中的財務指引僅以今日為準。除法律要求外,我們的政策是不更新或確認指引。接下來,我很高興把電話交給 Joe。

  • - Chairman & CEO

    - Chairman & CEO

  • Thank you, Elif. Good morning, everyone. Thank you for joining us today. Let me take a minute just to run through the topics we will cover this morning. I'm going to kick off the call with some brief remarks about the progress we made in 2016 to create the new Valeant, focusing on performance updates since our third-quarter call in November of 2016.

    謝謝你,Elif。各位早安。感謝各位今天加入我們。我先花一點時間說明今天上午我們將涵蓋的主題。我將以一些簡短的評論開場,談談我們在 2016 年為打造「新 Valeant」所取得的進展,並著重於自 2016 年 11 月第三季電話會議以來的績效更新。

  • I will then hand off to Paul Herendeen to review our fourth-quarter and the full-year of 2016 financial results, both for the Company as a whole and for each of our three reportable business segments. He will also talk us through the guidance for 2017. Then I will share my perspective on our business, our new product pipeline, and what you can expect for the remainder of 2017.

    接著我會交給 Paul Herendeen,回顧我們 2016 年第四季及全年財務業績,包括公司整體以及三個可報告營運部門各自的表現。他也會帶大家了解 2017 年的指引。然後我將分享我對我們業務、我們的新產品研發管線,以及 2017 年剩餘期間各位可以期待的事項之看法。

  • So, let's get started with slide 4. I am not going to talk to each of these points in detail, but you can see from this list that there were numerous positive developments in the last quarter of the year-end the first quarter of 2017 is off to a good start.

    那麼,讓我們從第 4 頁投影片開始。我不會逐點詳細說明,但從這份清單可以看到,在年末最後一季出現了許多正面進展,而 2017 年第一季也有一個良好的開局。

  • First, Paul will walk through the Q4 of 2016 in greater detail, but importantly our Q4 revenues and adjusted EBITDA were in line with revised guidance and we have delivered on our Q4 commitments. In terms of divestitures and debt reduction, we have been able to reduce the complexity of the portfolio by agreeing to divest CeraVe, AcneFree and AMBI to L'Oreal for $1.3 billion and Dendreon to the Sanpower Group for $819.9 million.

    首先,Paul 會更詳細說明 2016 年第四季,但重要的是,我們第四季營收與調整後 EBITDA 符合修訂後的指引,我們也兌現了第四季的承諾。在資產剝離與減債方面,我們已同意將 CeraVe、AcneFree 與 AMBI 以 13 億美元出售給萊雅(L'Oreal),並將 Dendreon 以 8.199 億美元出售給三胞集團(Sanpower Group),從而降低投資組合的複雜度。

  • We are also in the process of divesting certain businesses in several non-core geographies including Vietnam, Indonesia, and Brazil. Finally, we closed on the sale of Ruconest and realized additional milestones for our OEM business.

    我們也正在進行於多個非核心地區的特定業務剝離,包括越南、印尼與巴西。最後,我們已完成 Ruconest 的出售,並為我們的 OEM 業務達成額外的里程碑。

  • The proceeds from these divestitures will enable us to deliver on our commitment of paying down debt. In 2016, we paid down approximately $1.84 billion of permanent debt, which included $519 million since the third quarter. During 2016, we have made all of the amortization payments due in 2017.

    這些資產剝離的所得將使我們能夠履行償還債務的承諾。2016 年,我們償還了約 18.4 億美元的永久性債務,其中包括自第三季以來的 5.19 億美元。在 2016 年期間,我們已支付所有於 2017 年到期的攤還款項。

  • Also as we announced yesterday, we have recruited and launched a new primary care salesforce for Xifaxan. We've also remediated the issues that arose at our Tampa manufacturing facility and we believe that our Tampa manufacturing quality process in that location are on track now.

    此外,如同我們昨天宣布的,我們已招募並啟動一支新的 Xifaxan 基層醫療銷售團隊。我們也已修復坦帕(Tampa)製造廠出現的問題,並相信該地點的製造品質流程目前已回到正軌。

  • We've hired new leadership for our dermatology business, which is recovering from past disruption. Importantly, we entered into an agreement in principle to settle the legacy 2014 Salix securities litigation for $210 million. The proposed settlement agreement remains subject to court approval. The amount has been fully accrued for in the Company's consolidated financial statements as of December 31, 2016.

    我們已為皮膚科業務聘任新的領導團隊,該業務正從過去的干擾中復原。重要的是,我們已達成原則性協議,以 2.10 億美元和解 2014 年 Salix 遺留的證券訴訟。擬議的和解協議仍須法院核准。截至 2016 年 12 月 31 日,該金額已在公司合併財務報表中全數提列。

  • Finally with respect to our pipeline, we have achieved several very important milestones. First, earlier this month, we received FDA approval for Siliq or brodalumab. We refiled latanoprostene bunod, Vyzulta, an innovative new treatment for glaucoma. We completed two successful Phase 3 studies of IDP-118, a topical psoriasis treatment. We also licensed EGP-437 from Eyegate Pharmaceuticals for a new eye care indication. We announced last week we are partnering with Nextcell to expand our Obagi franchise. We are launching incremental Bausch + Lomb Ultra lenses. We have signed a binding letter of intent to evaluate Relistor in an oncology indication.

    最後,關於我們的研發管線,我們已達成數個非常重要的里程碑。首先,本月稍早我們取得 Siliq(brodalumab)的 FDA 核准。我們重新遞交了 latanoprostene bunod(Vyzulta),這是一種創新的青光眼新療法。我們完成了 IDP-118(外用乾癬治療)的兩項成功第三期試驗。我們也自 Eyegate Pharmaceuticals 取得 EGP-437 的授權,用於新的眼科照護適應症。我們上週宣布與 Nextcell 合作,以擴大我們的 Obagi 產品系列。我們正在推出增量的 Bausch + Lomb Ultra 鏡片。我們已簽署具約束力的意向書,以評估 Relistor 在腫瘤適應症上的應用。

  • So from a new product pipeline perspective, we are improving the probability of future success. That said, we also experienced some recent challenges that have impacted our business and will likely have an effect on 2017 result. In the first quarter of 2017 we saw an increased salesforce turnover owing to some voluntary and involuntary changes. I'll discuss salesforce turnover in more detail later on, but we feel that we have addressed the issues and generally stabilized the turnover in our salesforce.

    因此,從新產品研發管線的角度來看,我們正在提高未來成功的機率。不過,我們近期也遭遇一些挑戰,已影響我們的業務,並可能對 2017 年業績造成影響。在 2017 年第一季,由於部分自願與非自願的變動,我們看到銷售團隊離職率上升。我稍後會更詳細討論銷售團隊流動,但我們認為已解決相關問題,並整體上使銷售團隊的流動趨於穩定。

  • Moving on to products, as we expected and announced in November 2016, a competitor, Nitropress, entered the market in December of 2016. In general, loss of exclusivity will impact the 2017 results. And finally for my process perspective, fourth-quarter realize pricing was down 3% year over year. We also experienced a significant devaluation in Egyptian currently and a continued decline in dermatology RX that negatively impacted fourth-quarter results.

    接著談到產品,如我們所預期並於 2016 年 11 月宣布的,競品 Nitropress 於 2016 年 12 月進入市場。整體而言,獨占權喪失將影響 2017 年的業績。最後,從定價流程的角度來看,第四季實現價格較去年同期下降 3%。我們也經歷埃及貨幣的大幅貶值,以及皮膚科處方(RX)持續下滑,對第四季業績造成負面影響。

  • But even with those headwinds, from my perspective, the team has accomplished a great amount since May 2016. I am proud of the efforts of this leadership team to create the new Valeant, to create good solutions for our patients and importantly to create long-term value for our shareholders. On that note, I'm going to turn it over to Paul to go through the fourth-quarter and full-year 2016 financial results.

    但即使面對這些逆風,從我的角度來看,自 2016 年 5 月以來,團隊已完成了大量工作。我為這個領導團隊打造「新 Valeant」的努力感到自豪,為病患提供良好解決方案,更重要的是為股東創造長期價值。基於此,我將把電話交給 Paul,請他說明 2016 年第四季及全年財務業績。

  • - CFO

    - CFO

  • Thanks, Joe. Before I start, let me point out that when I talk about adjusted numbers, those are non-GAAP measures and we provide reconciliations of all adjusted amounts to the related GAAP measures in the appendix to the slides on our website. Next, as I stated last quarter, from here forward, we intend to focus on revenue and adjusted EBITDA as our primary performance and valuation metrics.

    謝謝你,Joe。在我開始之前,先指出當我談到調整後數字時,那些是非 GAAP 指標;我們在網站投影片附錄中提供所有調整後金額與相關 GAAP 指標之間的調節表。接著,如同我上季所說,從現在起,我們打算以營收與調整後 EBITDA 作為主要的績效與估值衡量指標。

  • First, the headlines. Revenue for the year came in at $9.674 billion, slightly above the high end of our revised guidance range which we provided in early November. Our adjusted EBITDA is right in the middle of the guidance range and our adjusted net income per share of $5.47 was in the upper portion of the range.

    首先,先看重點摘要。全年營收為 96.74 億美元,略高於我們在 11 月初提供之修訂後財測區間的上緣。我們的調整後 EBITDA 正好落在財測區間的中間,而調整後每股淨利 5.47 美元則位於區間的較高端。

  • The team here is working hard every day to improve our ability to forecast our various businesses. It was an important step for us to meet the expectations that we set for the quarter.

    這裡的團隊每天都在努力提升我們對各項業務的預測能力。本季能達成我們所設定的預期,對我們而言是重要的一步。

  • So, okay, let's start, top level look at our results for the fourth quarter. In the quarter, we posted revenue of $2.403 billion, roughly a 13% decline when compared with Q4 of 2015. The B+ L/International segment revenue was roughly flat, down 1% on a reported basis but adjusted for currency, which was a headwind of roughly 360 basis points, was up 2.6%. On a constant currency basis, pricing across the B&L and the International segment increased revenue by 1.7% and volume was up contributing about 0.5% of growth.

    好,那我們先從高層次來看第四季的整體表現。本季營收為 24.03 億美元,與 2015 年第四季相比約下滑 13%。B+L/International(B+L/國際)事業部營收大致持平,按報告口徑下滑 1%,但若剔除匯率影響(約 360 個基點的不利因素)後,則成長 2.6%。以固定匯率計,B&L 與國際事業部的價格因素使營收增加 1.7%,銷量上升亦貢獻約 0.5% 的成長。

  • Note that in Q4, we continued to reduce the level of pipeline inventories in our Eastern European cluster, mainly in Poland. That had the effect of reducing our performance compared with the prior-year quarter. The branded RX segment in the quarter declined 17%, with roughly half of the decline coming from our GI business and half from our derm business. The GI business was down 17% compared with the prior-year quarter, with the decline almost all on volume as net pricing was about the same.

    請注意,第四季我們持續降低東歐區域(主要在波蘭)的通路庫存水位。這使得我們相較於去年同期的表現受到壓抑。本季品牌處方藥(branded RX)事業部下滑 17%,其中約一半的下滑來自腸胃(GI)業務,另一半來自皮膚科(derm)業務。GI 業務較去年同期下滑 17%,幾乎全部來自銷量下滑,因為淨價格大致持平。

  • The decline in the GI business compared with Q4 of 2015 is mainly due to the loss of exclusivity with Glumetza and Zegerid and the transfer of the Zegerid authorized generic out of the GI business and into our generics business, which is in our diversified segment. Together Glumetza, Zegerid and the transfer of the Zegerid AG reduced our GI unit revenue by some $128 million. The balance of our promoted GI brands, Xifaxan, Uceris, and Apriso were up 13% compared with Q4 of 2015.

    GI 業務相較 2015 年第四季的下滑,主要是因 Glumetza 與 Zegerid 失去獨家銷售權(LOE),以及將 Zegerid 的授權學名藥(authorized generic)自 GI 業務移轉至我們的學名藥業務(隸屬多元化事業部)。Glumetza、Zegerid 以及 Zegerid AG 的移轉合計使 GI 單位營收減少約 1.28 億美元。其餘我們主力推廣的 GI 品牌(Xifaxan、Uceris 與 Apriso)較 2015 年第四季成長 13%。

  • Pipeline inventories in the GI business increased roughly 0.1 of a month in the fourth quarter and relative to the prior-year quarter the net expansion of pipeline inventories was roughly 0.2 of a month. So a portion of that 13% growth of the promoted brands was due to the relative pipeline expansion. Year-end pipeline inventories in GI stood at 1.57 months compared with 1.8 months at the end of 2015.

    第四季 GI 業務的通路庫存約增加 0.1 個月;相較去年同期,通路庫存的淨增加約為 0.2 個月。因此,主力推廣品牌 13% 的成長中,有一部分來自相對的通路庫存擴張。GI 年底通路庫存為 1.57 個月,2015 年底則為 1.8 個月。

  • Our derm business was down 28% compared with Q4 of 2015. A reduction in realized prices reduce revenue by about 6% compared with Q4 2015, as we transitioned in late 2015 and early 2016 away from a specialty pharmacy model to our current model that features our unique relationship with Walgreens, supported by increased contracting with Managed Care to provide patients with access to our products and finally co-pay assistance programs to help bridge potential affordability gaps from patients.

    我們的皮膚科(derm)業務較 2015 年第四季下滑 28%。隨著我們在 2015 年底與 2016 年初從專科藥局模式轉向目前的營運模式(包含與 Walgreens 的獨特合作關係、並透過加強與管理式醫療(Managed Care)的合約以提供病患取得產品的管道,以及自付額(co-pay)補助計畫以協助彌補病患可能的負擔落差),實現價格(realized prices)的下降使營收較 2015 年第四季減少約 6%。

  • Volume in the derm business was down 24% as we saw a dramatic decrease in the refill rates for our prescriptions under the new model as compared with the old. In the latter part of 2016, the derm team was able to get new prescription volumes back to near last year's levels. Pipeline inventories in the derm business decreased by roughly 0.36 months in the fourth quarter but relative to the prior-year quarter, pipeline inventories expanded by just more than 0.1 of a month. Year-end pipeline inventories in derm stood at 1.34 months compared with roughly one month at the end of 2015.

    皮膚科業務的銷量下滑 24%,因在新模式下,我們處方的續配率(refill rates)相較舊模式大幅下降。在 2016 年後期,皮膚科團隊已能將新處方量拉回接近去年水準。皮膚科業務的通路庫存於第四季約下降 0.36 個月,但相較去年同期,通路庫存仍擴張略高於 0.1 個月。皮膚科年底通路庫存為 1.34 個月,2015 年底約為 1 個月。

  • Revenues in the diversified segment were down roughly 30% with most of that decline coming from the neurology business, which decreased 35%. Decreases in realized prices across the neuro portfolio reduced revenue approximately 15% and the remaining, roughly 20%, decline came from decreased volume. Our neuro portfolio had a number of LOE's that impacted Q4 2016 versus Q4 2015 including Xenazine, Mestinon, Ammonul and Sodium Edecrin.

    多元化事業部營收約下滑 30%,其中大部分下滑來自神經科(neurology)業務,該業務下滑 35%。神經科產品組合的實現價格下降使營收減少約 15%,其餘約 20% 的下滑來自銷量下降。我們的神經科產品組合有多項失去獨家銷售權(LOE)事件,影響 2016 年第四季相較 2015 年第四季的表現,包括 Xenazine、Mestinon、Ammonul 與 Sodium Edecrin。

  • Pricing in the neuro business declined due to increased Managed Care rebates, lower price appreciation credits relative to the prior year-end higher group purchasing discounts provided for products including Isuprel and Nitropress. Our generics business was also off, declining roughly 19% compared with the prior-year quarter and the main reason was the relative change in pipeline inventories. In Q4 of 2016, pipeline inventories for genetics decreased 0.16 months on hand. In Q4 of 2015, we saw a pipeline expansion of 0.41 months. So the relative impact of the pipeline inventories was almost 0.6 of a month, which accounts for a good portion of the decrease in Q4 2016 versus Q4 2015.

    神經科業務的定價下滑,原因包括管理式醫療(Managed Care)回扣增加、相較去年年底較低的價格增值抵減(price appreciation credits),以及針對包括 Isuprel 與 Nitropress 等產品提供較高的團體採購折扣。我們的學名藥業務也走弱,較去年同期下滑約 19%,主要原因是通路庫存的相對變動。2016 年第四季,學名藥的通路庫存(以在手月數計)下降 0.16 個月。2015 年第四季則出現 0.41 個月的通路庫存擴張。因此通路庫存的相對影響接近 0.6 個月,解釋了 2016 年第四季相較 2015 年第四季下滑的相當一部分。

  • Year-end pipeline inventories in our generics business went from 1.46 months at year-end 2015 to 1.01 months at the end of 2016. Adjusted gross margin in the fourth quarter decreased by some 330 basis points compared with Q4 2015, with about half of that due to the change in mix of revenues with our two higher gross margin businesses, branded RX and diversified, declining and B+ L's International holding relatively steady.

    我們學名藥業務的年底通路庫存由 2015 年底的 1.46 個月降至 2016 年底的 1.01 個月。第四季調整後毛利率較 2015 年第四季下降約 330 個基點,其中約一半是因營收組合改變所致:兩個毛利率較高的業務(品牌處方藥與多元化事業部)下滑,而 B+L 的國際業務相對持穩。

  • About 10% of the decreased margin was due to the degradation of our gross to net in our branded RX business -- segment and 40% from FX in our B+ L/International segment. Our adjusted operating expenses were favorable to the prior-year quarter with SG&A expenses down 3.5% or $24 million compared with the prior year. This was mainly due to decreased A&P spending in our derm and GI businesses, which were offset by higher selling expenses in G&A -- offset in part.

    毛利率下滑中約 10% 來自品牌處方藥事業部的「毛額到淨額」(gross to net)惡化,另有 40% 來自 B+L/International 事業部的匯率(FX)影響。我們的調整後營業費用優於去年同期,SG&A 費用較去年同期下降 3.5%,或 2,400 萬美元。這主要是因皮膚科與 GI 業務的 A&P(廣告與促銷)支出下降,但部分被較高的銷售費用與 G&A(一般與行政)費用所抵銷——部分抵銷。

  • Adjusted R&D expense was down slightly compared with Q4 of 2015. I want to point out that this was simply how our R&D expenses fell for the quarter and was not due to us cutting or delaying R&D programs. We're committed to our investment in R&D and expect to invest more in 2017 than in 2016.

    調整後研發(R&D)費用較 2015 年第四季小幅下降。我想強調,這只是本季研發費用入帳時點的結果,並非我們削減或延後研發計畫所致。我們承諾持續投入研發,並預期 2017 年的研發投資將高於 2016 年。

  • So the quarter in a nutshell, the 13% drop in revenue in Q4 versus Q4 of 2015 combined with the gross margin decrease resulted in gross profit declining $343 million or 17%. That was offset a bit by roughly $27 million in reduced operating expenses resulting in adjusted EBITDA declining some 24% compared with the prior-year quarter to $1.046 billion.

    簡而言之,2016 年第四季相較 2015 年第四季營收下滑 13%,再加上毛利率下降,導致毛利減少 3.43 億美元或 17%。部分影響被營業費用減少約 2,700 萬美元所抵銷,使調整後 EBITDA 較去年同期下滑約 24% 至 10.46 億美元。

  • Adjusted net income per share fell 19%, not as much as adjusted EBITDA as taxes were favorable compared with the prior-year quarter. Our effective tax rate on adjusted pretax earnings in Q4 of 2016 was 15.8% versus 39.5% in the prior-year quarter. Important safety tip, effective tax rates in any one quarter can be volatile and in the fourth quarter of 2015, we had to catch up our full-year provision to what ended up being a 22.8% effective tax rate on adjusted pretax earnings for the full year.

    調整後每股淨利下滑 19%,降幅小於調整後 EBITDA,因稅負較去年同期更有利。2016 年第四季調整後稅前盈餘的有效稅率為 15.8%,去年同期為 39.5%。重要安全提示:單一季度的有效稅率可能波動很大;在 2015 年第四季,我們必須追補全年稅費提列,最終使全年調整後稅前盈餘的有效稅率為 22.8%。

  • Our adjusted tax rate for the full year of 2016 was 15.5% and that is favorable to the 22.8% that we saw in 2015. That's based on the shift in the jurisdictional mix of income with several of our more profitable US business units seeing meaningful year-over-year declines in revenue and therefore taxable income. A portion of the favorable tax variance was offset by an increase in interest expense of $34 million primarily driven by an increase in interest expense due to the two amendments to our credit facility in 2016, an increase in our revolver borrowings, and rising rates. That was partially offset by the reduction in debt.

    我們2016年全年的調整後有效稅率為15.5%,相較於2015年的22.8%更為有利。這主要是由於所得在各司法管轄區的組合發生變化:我們數個獲利能力較高的美國業務單位,其營收因年對年顯著下滑,因而應稅所得亦下降。部分有利的稅務差異被利息費用增加3,400萬美元所抵銷;該增加主要由2016年對我們信貸融資安排的兩次修訂、循環信貸借款增加,以及利率上升所致。上述影響又因債務減少而部分抵銷。

  • Moving on to the full year 2016 as compared with 2015. High level, revenue decreased $773 million or 7%, excluding the favorable impacts from the Salix and Amoun acquisitions, our revenue decreased some 13%. B+ L revenue was flat aided by the impact of the Amoun acquisition and held back by unfavorable movements in FX rates that reduced 2016 revenues by some $125 million relative to 2015. In branded RX, the $434 million or 12% decline was a result of dermatology pricing and volume falling dramatically and overwhelming the $339 million favorable impact from the acquisition of Salix, which was acquired on April 1 of 2015, so it is not in 2015 for full year.

    接著看2016年全年相較於2015年。整體而言,營收減少7.73億美元或7%;若排除Salix與Amoun收購案帶來的有利影響,我們的營收約下降13%。B+L營收在Amoun收購案影響的支撐下持平,但不利的匯率變動使2016年營收相較2015年減少約1.25億美元。在品牌處方藥(branded RX)方面,營收下降4.34億美元或12%,係因皮膚科產品的價格與銷量大幅下滑,抵銷了收購Salix帶來的3.39億美元有利影響;Salix於2015年4月1日收購,因此2015年並未反映全年貢獻。

  • Degradation in our gross to net, that's Managed Care rebates, coupon cards, et cetera, in both GI and derm, but mainly derm, resulted in our realized net pricing falling and reducing revenue by some $430 million compared with the prior year. Revenue in our diversified segment fell some $342 million or 15%, mainly driven by a 20% drop in volume from the impact of LOE's in our neuro portfolio. We saw growth in our generics business coming from increased volume, mainly from the addition of the Zegerid authorized generic to the portfolio, which more than offset downward pricing pressure in the generics business.

    我們的「毛額到淨額」(gross to net)惡化——包括醫療保險(Managed Care)回扣、折價券卡等——在GI與皮膚科兩者皆有發生,但主要在皮膚科,導致實現的淨售價下降,使營收較前一年減少約4.30億美元。多元化(diversified)部門營收下降約3.42億美元或15%,主要因神經科產品組合受專利到期(LOE)影響,銷量下滑20%。我們的學名藥業務因銷量增加而成長,主要來自將Zegerid授權學名藥納入產品組合,其增量足以抵銷學名藥業務的降價壓力。

  • A little more detail for each of the segments for the full year. The B+ L/International segment was flat compared with the prior year, the changes in FX rates reduced 2016 revenue relative to 2015 by some 280 basis points or $125 million. Acquisitions net of divestitures mainly Amoun, added some $203 million to revenue. So excluding acquisitions and adjusting for FX, the underlying business declined some 1.6% year over year. We saw price erosion in the segment, which decreased revenue on an FX neutral basis by some 215 basis points or $98 million. This was driven mainly by the US ophthalmology RX business, due to increased Managed Care rebating needed to maintain patient access for our products.

    以下提供各部門全年表現的更多細節。B+L/國際部門相較前一年持平;匯率變動使2016年營收相較2015年減少約280個基點或1.25億美元。收購扣除處分(主要為Amoun)使營收增加約2.03億美元。因此,若排除收購並調整匯率影響,基礎業務年對年下滑約1.6%。該部門出現價格侵蝕,在匯率中性基礎下使營收減少約215個基點或9,800萬美元。此主要由美國眼科處方藥業務所致,因為為維持患者對我們產品的可近性,需要提高醫療保險回扣。

  • The international portion of the B+ L segment on an FX neutral basis actually saw pricing gains in 2016 versus 2015 mainly in Latin America and Asia-PAC regions. Adjusted for FX, overall segment volume improved slightly in the increasing of revenue by some 65 basis points or $31 million. That was a US consumer in China doing quite well, but offset in part by weakness in South Asia and Eastern Europe, where we took hits to reduce the level of pipeline inventories of our products held by our customers.

    B+L部門中的國際部分在匯率中性基礎下,2016年相較2015年實際上出現價格成長,主要發生在拉丁美洲與亞太地區。在調整匯率後,整體部門銷量略有改善,使營收增加約65個基點或3,100萬美元。這主要是我們在中國的美國消費者業務表現相當良好,但部分被南亞與東歐的疲弱所抵銷;在這些地區,我們為降低客戶持有的本公司產品管線庫存水位而受到影響。

  • Selling expenses in the segment were $65 million higher due to the acquisition of Amoun and hit the selling expense for our US ophthalmology RX business from the Walgreens' agreements as the per RX charge paid to Walgreens is classified as a selling expense. In the branded RX segment, which declined $343 million or 12% compared with 2015, a reduction that realized pricing reduced revenue by some $431 million with roughly three-quarters of that, $323 million in our derm business and most of the balance about $120 million in our GI business.

    該部門的銷售費用增加6,500萬美元,原因包括收購Amoun,以及Walgreens協議對我們美國眼科處方藥業務銷售費用的影響;因支付給Walgreens的每張處方(per RX)費用被歸類為銷售費用。在品牌處方藥部門方面,2016年相較2015年下降3.43億美元或12%;其中,實現價格下降使營收減少約4.31億美元,約四分之三(3.23億美元)來自皮膚科業務,其餘大部分約1.20億美元來自GI業務。

  • In the shift from the specialty pharmacy model, we contracted with Managed Care to provide patient access to our derm products and offered substantial rebates. We also saw a degradation of our dermatology gross to net from the implementation of the Walgreens agreement, as we iterated to reasonable net selling prices for our derm products later in the year, but realized very low net pricing on our derm products early on.

    在從專科藥局模式轉型的過程中,我們與醫療保險機構簽約以提供患者對皮膚科產品的可近性,並提供大幅回扣。我們也因導入Walgreens協議而看到皮膚科「毛額到淨額」惡化;我們在年內後期逐步調整至合理的淨售價,但在初期對皮膚科產品實現的淨售價非常低。

  • In GI, early in Q1 of 2016, we elected to contract with Managed Care to ensure that patients for the IBSD indication for Xifaxan would have access to the product. Of course, that impacted the average selling price of all the Xifaxan franchise in 2016 relative to 2015.

    在GI方面,2016年第一季初,我們選擇與醫療保險機構簽約,以確保Xifaxan用於IBSD適應症的患者能取得該產品。當然,這也影響了2016年相較2015年整個Xifaxan產品線的平均售價。

  • On the volume side, the 25% volume decline in derm, roughly $370 million, overwhelmed the modest gains in GI where volume was up 3% excluding the acquisition impact. Note that the impact of acquisitions, net of some small divestitures, added roughly $362 million year-over-year growth for the segment. That was mainly from the acquisition of Salix in April 2015.

    在銷量方面,皮膚科銷量下降25%,約3.70億美元,壓過了GI的溫和成長;若排除收購影響,GI銷量增加3%。請注意,收購影響扣除少量處分後,為該部門帶來約3.62億美元的年對年成長。這主要來自2015年4月收購Salix。

  • Selling expense in the branded RX business in 2016 compared with 2015 was negatively impacted by the Walgreens agreement in the derm business, a full year of Salix selling expenses, cost to begin building the Xifaxan primary care salesforce later in the year. It was partially offset by expense discipline in 2016. A&P was favorable by $88 million mainly in lesser A&P spending for DTC advertising in the derm and GI businesses relative to 2015.

    2016年品牌處方藥業務的銷售費用相較2015年受到不利影響,原因包括皮膚科業務的Walgreens協議、Salix全年銷售費用,以及年內後期開始建立Xifaxan基層醫療(primary care)銷售團隊的成本。部分影響被2016年的費用控管所抵銷。廣告與促銷(A&P)費用有利8,800萬美元,主要因皮膚科與GI業務的DTC(直接面向消費者)廣告支出相較2015年較少。

  • In the diversified segment, total revenue declined $342 million. Excluding the impact from acquired assets and that of divestitures, the decline was $421 million, with a $122 million from reductions in realized pricing and $299 million from volume declines.

    在多元化部門,總營收下降3.42億美元。若排除收購資產以及處分的影響,降幅為4.21億美元,其中1.22億美元來自實現價格下降,2.99億美元來自銷量下滑。

  • Pricing in the neuro business declined due to increased Managed Care rebates, lower price appreciation credits relative to the prior-year quarter and higher group purchasing discounts provided for products including Isuprel and Nitropress. As in the quarter, LOE's were a big factor in the volume decline for the year including Xenazine, Mestinon, Ammonul and Sodium Edecrin. Compared with 2015, Nitropress declined $89 million, Xenazine $66 million, Isuprel $46 million, Wellbutrin $27 million and the balance of the balance of the portfolio was down $266 million. The declines were partially offset by the growth of Migranal which was plus $20 million, the Zegerid AG which added $98 million of growth relative to 2015, and Cuprimine up $34 million.

    神經科業務的價格因醫療保險回扣增加、相較前一年同期較低的價格增值抵減(price appreciation credits),以及對包括Isuprel與Nitropress等產品提供較高的團體採購折扣而下降。如同季度表現,專利到期(LOE)是全年銷量下滑的重要因素,包括Xenazine、Mestinon、Ammonul與Sodium Edecrin。相較2015年,Nitropress減少8,900萬美元、Xenazine減少6,600萬美元、Isuprel減少4,600萬美元、Wellbutrin減少2,700萬美元,其餘產品組合下降2.66億美元。上述下滑部分被Migranal成長(增加2,000萬美元)、Zegerid授權學名藥(Zegerid AG)相較2015年增加9,800萬美元,以及Cuprimine增加3,400萬美元所抵銷。

  • Adjusted gross margin for the full-year decreased by some 340 basis points, same basic story as with the fourth quarter, about half of the decrease in the average margins is due to the change in mix of revenues with the two higher gross margin businesses, branded RX and diversified, declining and B+ L holding relatively steady. The degradation of Ruconest accounted for about 25% of decline and FX accounted for about 25% of the decline in gross margins compared with 2015.

    全年調整後毛利率下降約340個基點;基本情況與第四季相同,平均毛利率下降約一半是由於營收組合改變所致:兩個毛利率較高的業務——品牌處方藥與多元化——下滑,而B+L相對持穩。Ruconest的惡化約占毛利率下降的25%,匯率因素約占相較2015年毛利率下降的25%。

  • Total adjusted SG&A expenses for the year were $89 million unfavorable to 2015. We had lesser advertising and promotion expenses in our derm and GI business, offset by some increases in selling expense while our full-year adjusted G&A expenses were unfavorable compared with 2015 by some $106 million.

    全年調整後SG&A總費用較2015年不利8,900萬美元。我們在皮膚科與GI業務的廣告與促銷費用較少,但被部分銷售費用增加所抵銷;同時,全年調整後一般及行政(G&A)費用相較2015年不利約1.06億美元。

  • In adjusted G&A, we incurred significant costs for outside services for a number of special projects including the restatement of our financial statements, the material weakness remediation, and the costs of consultants brought in to assist with our zero-based budgeting initiative and a supply chain rationalization project.

    在調整後的一般及行政費用(G&A)中,我們因多項特殊專案而發生了可觀的外部服務成本,包括重編我們的財務報表、重大缺失補救,以及聘請顧問協助推動零基預算(zero-based budgeting)計畫與供應鏈合理化專案的費用。

  • We also incurred a number of employee related costs in 2016 mainly severance, retention, and sign-on bonuses. None of these items are excludable from operating expense under our policies for determining adjusted EBITDA, so they reduced our adjusted EBITDA in 2016 relative to 2015.

    我們在2016年也發生了多項與員工相關的成本,主要為資遣費、留任獎金與到職簽約獎金。依我們用以決定調整後EBITDA的政策,這些項目均不得自營業費用中排除,因此相較於2015年,它們使我們2016年的調整後EBITDA下降。

  • We increased our investment in adjusted R&D by some $72 million compared with 2015. We remain committed to increasing the level of funding for R&D as we go forward. So in summary for the year, the $775 million or 7% reduction in revenue combined with the 340 basis point decrease in adjusted gross margins resulted in adjusted gross profit declining faster than revenue and was down 11.5%, a $924 million drop. Total operating expenses were unfavorable by some $161 million with 45% of that increase coming from our re-increased investment in R&D. Adjusted EBITDA fell by 20% to $4.304 billion.

    相較於2015年,我們在調整後研發(R&D)上的投資增加約7,200萬美元。我們仍致力於在未來持續提高研發資金投入水準。因此,總結全年,營收減少7.75億美元(或7%),再加上調整後毛利率下降340個基點,導致調整後毛利下滑速度快於營收,下降11.5%,減少9.24億美元。營業費用總額不利增加約1.61億美元,其中45%的增幅來自我們重新加大研發投資。調整後EBITDA下降20%至43.04億美元。

  • Below the operating line, we had roughly $269 million more interest expense in 2016 than in 2015, as we [totaled] the full-year impact of the debt used to fund acquisitions, mainly the Salix acquisition. Our effective tax rate on adjusted pretax earnings declined from 22.8% for 2015 to 15.5% for the full year 2016 mainly due to the jurisdictional mix of pretax earnings as I discussed a moment ago with respect to the fourth quarter. Adjusted net income per share fell 33% to $5.47 per share.

    在營業利益線以下,2016年的利息費用較2015年約增加2.69億美元,因為我們反映了用於資助收購(主要為Salix收購案)之負債的全年影響。我們在調整後稅前盈餘上的有效稅率,從2015年的22.8%降至2016年全年的15.5%,主要由於稅前盈餘的司法管轄區組合(jurisdictional mix),正如我稍早在談到第四季時所提及。調整後每股淨利下降33%至每股5.47美元。

  • Before I turn to the balance sheet and liquidity, let me update you on our progress in our efforts to simple our portfolio and reduce debt through assets sales. To date, we have divested or agreed to divest 10 businesses for total gross proceeds of up to $2.7 billion. Our most significant divestitures are the sale of our skincare assets to L'Oreal, which is expected to close in the first quarter of 2017 and the sale of Dendreon to Sanpower, which is expected to close midyear.

    在我轉到資產負債表與流動性之前,先向各位更新我們透過資產出售以簡化投資組合並降低負債的進展。截至目前,我們已完成或已同意出售10項業務,總毛收益最高可達27億美元。我們最重要的資產處分包括將護膚資產出售給萊雅(L'Oreal)(預計於2017年第一季完成交割),以及將Dendreon出售給三胞(Sanpower)(預計於年中完成交割)。

  • Turning to our balance sheet and liquidity, we generated just under $2.1 billion of net cash from operating activities in calendar 2016 and reduced total debt by roughly $1.2 billion. We ended the year with $30.1 billion in principal amount of funds to debt outstanding and cash on hand of $542 million. We currently have $875 million drawn on our $1.5 million revolver.

    談到資產負債表與流動性,我們在2016曆年由營業活動產生的淨現金略低於21億美元,並將總負債減少約12億美元。年底時,我們未償還債務本金總額為301億美元,手上現金為5.42億美元。目前我們在15億美元的循環信貸額度(revolver)下已動用8.75億美元。

  • In 2016, we satisfied all of our mandatory debt repayments for 2017. We continually monitor the capital markets and we'll look for opportunities to increase our operating flexibility and extend the maturity profile of our debt.

    在2016年,我們已滿足2017年所有強制性債務償還要求。我們將持續監控資本市場,並尋找機會提升營運彈性並延長債務到期結構。

  • Now, what I'm sure lots are waiting for, turning to our guidance for 2017. First, we are providing guidance for revenue and adjusted EBITDA. We believe these are the most appropriate performance and valuation metrics for our Company. However, we are also providing information a model would want and need to forecast some form of adjusted net income and adjusted net income per share, as well as to forecast cash flows and our balance sheet.

    接下來,進入我相信許多人都在等待的部分:我們對2017年的財測指引。首先,我們提供營收與調整後EBITDA的指引。我們認為這些是最適合用來衡量本公司績效與估值的指標。不過,我們也會提供模型在預測某種形式的調整後淨利與調整後每股淨利時所希望且需要的資訊,以及用於預測現金流與資產負債表的資訊。

  • I want to point out that our definition of adjusted EBITDA is intended to be right in the middle of the fairway. We start with GAAP EBIT and we add back to that amortization, depreciation, non-cash share based comp, restructuring costs, legal settlements, impairments or goodwill or other intangibles, acquisition related contingent consideration, IP R&D, milestone payments and legal or other professional fees that are related to legacy Valeant matters.

    我想指出,我們對調整後EBITDA的定義,意在落在「公平球道的正中央」。我們從GAAP EBIT開始,並加回攤銷、折舊、非現金的股份基礎薪酬、重組成本、法律和解金、減損(商譽或其他無形資產)、與收購相關的或有對價、IP研發、里程碑付款,以及與Valeant歷史事項相關的法律或其他專業費用。

  • Our goal is to have these items be easy to find in our GAAP financial statements, footnotes and related disclosures. We will keep you updated on our expectations with respect to the items below the operating earnings line, that's mainly interest expense and our effective tax rate on adjusted earnings. With this information, it should be relatively straightforward for parties to model our business down to their own definition of net income and net income per share.

    我們的目標是讓這些項目能在我們的GAAP財務報表、附註及相關揭露中容易查找。我們也會持續向各位更新對營業利益線以下項目的預期,主要是利息費用以及調整後盈餘的有效稅率。有了這些資訊,各方應可相對容易地將我們的業務建模,並推導至其自身對淨利與每股淨利的定義。

  • Our guidance is based on current FX rates and does not assume that either the potential sales of skincare assets to L'Oreal or the potential sale of Dendreon to Sanpower close. So our guidance for 2017 is for revenue in the range of $8.9 billion to $9.1 billion and adjusted EBITDA in the range of $3.55 billion to $3.70 billion.

    我們的指引係以目前匯率為基礎,且不假設護膚資產出售給萊雅(L'Oreal)或Dendreon出售給三胞(Sanpower)等潛在交易完成交割。因此,我們2017年的指引為:營收介於89億至91億美元,調整後EBITDA介於35.5億至37.0億美元。

  • Let me call your attention to a few of the other pieces of information that are shown on the guidance slide. The expected interest for 2017 of approximately $1.85 billion includes roughly $100 million of amortization of deferred financing costs. Said another way, our cash interest cost in 2017 is expected to be roughly $1.75 billion. Importantly, when looking at interest coverage, cash interest is the important number.

    請各位注意指引投影片上所列的其他幾項資訊。2017年預期利息約18.5億美元,其中包含約1億美元的遞延融資成本攤銷。換句話說,我們2017年的現金利息成本預期約為17.5億美元。重要的是,在觀察利息保障倍數時,現金利息才是關鍵數字。

  • If you want to model our Company by segment and you want allocate R&D, take a look at our segment reporting to see the R&D that's directly allocated to the segments and then there is a balance that ends up in corporate. That could be allocated roughly 50/50 between the B+ L/International segment and the branded RX segment.

    若您想按部門(segment)為本公司建模並分攤研發費用,請參考我們的部門別報導,先看直接分配至各部門的研發,另外還有一部分會歸入公司層級(corporate)。該部分大致可按50/50分攤至B+L/International部門與品牌處方藥(branded RX)部門。

  • The item contingent consideration and milestones, which is roughly $230 million for 2017 includes the $130 million due to Astra Zeneca upon the approval -- that became due upon the approval of brodalumab. The $290 million to $330 million of restructuring in other includes the agreed-upon amount to settle the Salix securities litigation, that's $210 million but does not include possible recovery of some of that amount from insurance. There are also other assumptions shown on the slide that are meant to be helpful in your model.

    「或有對價與里程碑」項目在2017年約為2.30億美元,其中包含在brodalumab獲准時應付給阿斯特捷利康(Astra Zeneca)的1.30億美元——該款項已於核准時到期應付。「其他」中的重組費用約為2.90億至3.30億美元,其中包含為和解Salix證券訴訟而同意支付的金額,即2.10億美元,但不包含可能由保險追回的部分。投影片上亦列示其他假設,旨在協助您建立模型。

  • Okay, as I mentioned on the last call and subsequently at a number of investor conferences, a number of our products, particularly in our neurology business, face data on certain losses of exclusivity over the next year. Ordinarily, I would say that LOE's are simply a part of our business and that we should model them and talk about them in MD&A and move on; however, the magnitude of the LOE's that began to hit us in 2016 and are continuing into 2017 in my opinion mask the underlying near-term performance of our more enduring franchises. For these reasons, we believe it is worth looking at our 2017 guidance, adjusted for the impact of the LOE assets.

    好的,如我在上次電話會議以及之後在多場投資人會議中提到的,我們多項產品(特別是神經科業務)在未來一年將面臨某些確定的獨占權到期(loss of exclusivity, LOE)。一般而言,我會說LOE只是我們業務的一部分,我們應在MD&A中將其納入模型並加以討論後繼續往前;然而,我認為自2016年開始影響我們、並延續至2017年的LOE規模,掩蓋了我們較具持久性的核心產品線在短期內的基本表現。基於這些原因,我們認為有必要在檢視2017年指引時,將LOE資產的影響加以調整後再看。

  • We've included a slide identifying the assets that either went generic or were divested in 2016 and those that we currently expect to face generic competition in 2017. It's a fairly detailed slide. I think the information is there that you need to draw your own conclusions. We've shown both the actual 2016 revenue and gross profit for these assets by segment and on current estimates of the revenue and profit for 2017. That is what is included in our guidance.

    我們已加入一張投影片,辨識出2016年已轉為學名藥或已處分的資產,以及我們目前預期在2017年將面臨學名藥競爭的資產。這是一張相當詳細的投影片。我認為其中已提供您所需的資訊,以便自行得出結論。我們按部門列示了這些資產在2016年的實際營收與毛利,以及依目前估計的2017年營收與獲利。這些內容即已納入我們的指引之中。

  • Starting with 2000 -- now, if you flip to that slide that shows the bridge to revenue guidance, start with 2016 actual revenue. If you adjust for the impact of the LOE products and adjust to current FX rates, you can see the expected growth rate of the remaining business at 2% to 4%. Our core segments the B+ L/International segment adjusted for the LOE products and FX is projected to grow at 5% to 7% and the branded RX segment at 2% to 5%. The non-LOE portion of the diversified segment is expected to decline in the range of 7% to 10% in 2017 versus 2016.

    從 2000 年開始——現在,如果你翻到那張顯示營收指引橋接的投影片,先從 2016 年實際營收開始。如果你調整 LOE 產品的影響並以目前的匯率(FX)調整,你可以看到其餘業務的預期成長率為 2% 至 4%。我們的核心事業部門 B+L/International 部門在扣除 LOE 產品與匯率影響後,預計成長 5% 至 7%,而品牌處方藥(branded RX)部門為 2% 至 5%。多元化部門中非 LOE 的部分,預期 2017 年相較 2016 年將下滑 7% 至 10%。

  • First, let's look at the B+ L/International segment. The B+ L/International growth in 2017 again adjusted for LOE products and FX of 5% to 7% is aided a bit by the pipeline inventory reductions that occurred in Eastern Europe, mainly Poland and Russia in 2016. Longer term, we would expect this segment to be a solid mid single-digit grower.

    首先,我們來看 B+L/International 部門。B+L/International 在 2017 年(同樣已就 LOE 產品與匯率調整)的 5% 至 7% 成長,部分受惠於 2016 年在東歐(主要是波蘭與俄羅斯)發生的通路庫存去化。從較長期來看,我們預期該部門將是穩健的中段個位數成長動能來源。

  • The 2% to 5% adjusted growth of the branded RX business is below its near-term and longer-term potential, as we expected dermatology business to be rebased in 2017 declining an additional 8% to 10% from its 2016 levels before returning to growth in 2018 and beyond. The outlook for our derm business in 2018 and beyond is quite good and with our upcoming launch of Siliq around mid-year and hopefully the addition of IDP-118 into our portfolio in late 2018.

    品牌處方藥(branded RX)業務經調整後 2% 至 5% 的成長,低於其短期與長期的潛力,因為我們預期皮膚科業務將在 2017 年重新定基,較 2016 年水準再下滑 8% 至 10%,之後於 2018 年及更往後恢復成長。我們對 2018 年及以後的皮膚科業務展望相當樂觀,並且我們即將在年中左右推出 Siliq,且希望在 2018 年底將 IDP-118 納入我們的產品組合。

  • We have a number of upcoming LOE's in the derm portfolio including Solodyn, Acanya, and Elidel in 2018 followed by Zyclara in 2019. But we are expecting to be able to overcome the declines of those assets and grow our dermatology revenues through our new product launches.

    我們的皮膚科產品組合中有多項即將到期的 LOE,包括 2018 年的 Solodyn、Acanya 與 Elidel,接著 2019 年是 Zyclara。但我們預期能夠克服這些資產下滑的影響,並透過新產品上市來推動皮膚科營收成長。

  • Second, our GI business is projected to grow only modestly in 2017. On an adjusted basis roughly 3% in 2017. As we lost some momentum in the fourth quarter in part because of the disruption surrounding the possible sale of the unit. We expect to begin regaining our footing -- we expect to regain our footing in GI in the latter part of 2017 especially as the primary care salesforce ramps up its productivity.

    第二,我們的腸胃(GI)業務在 2017 年預計僅溫和成長。以調整後基礎計算,2017 年約為 3%。我們在第四季失去了一些動能,部分原因是圍繞該事業單位可能出售所造成的干擾。我們預期將開始重新站穩腳步——我們預期在 2017 年下半年,特別是當基層醫療(primary care)銷售團隊的生產力逐步提升時,GI 業務將恢復動能。

  • We're also anticipating lower prices in the GI business. We're looking for low single-digit growth in the GI business in 2017 before moving to high single-digit growth in 2018 and beyond. The diversified segment projected to decline 7% to 10% in 2017 versus 2016 will still face above average declines in 2018 as the full impact for the bolus of 2016/2017 LOE's flows through the segment. If the 2017 LOE's play out as assumed at this time, the diversified segment would face another 15% to 20% decline in 2018 before seeing its decline rate moderate to the high to mid single-digits from there forward. That should give you a lot to think about with respect to our revenue.

    我們也預期 GI 業務的價格將走低。我們預期 2017 年 GI 業務為低個位數成長,之後在 2018 年及更往後提升至高個位數成長。多元化部門在 2017 年相較 2016 年預計下滑 7% 至 10%,而在 2018 年仍將面臨高於平均的下滑,因為 2016/2017 年那一波 LOE 的完整影響將在該部門反映出來。如果 2017 年的 LOE 如目前假設般發展,多元化部門在 2018 年將再下滑 15% 至 20%,之後其下滑幅度將趨緩至高到中個位數。這應該能讓你在思考我們的營收時有很多可供參考的資訊。

  • We provided a chart showing a range of compound annual growth rate assumptions for our three segments. But I thought it was quite important to provide some additional color regarding 2017 and 2018. Important note, we will update our assumptions with respect to the LOE assets throughout the year, but to be clear, even if we are fortunate enough to maintain exclusivity a bit longer, the LOE's are going to happen, it's just a question of when.

    我們提供了一張圖表,展示對三個部門所採用的一系列複合年成長率(CAGR)假設。但我認為針對 2017 年與 2018 年提供一些額外說明相當重要。重要提醒:我們將在全年持續更新對 LOE 資產的假設;但要說清楚的是,即使我們很幸運能多維持一段時間的獨占性,LOE 終究會發生,差別只是時間點。

  • The next slide which is the bridge to adjusted EBITDA uses the same methodology to show the growth of adjusted EBITDA suggested by our guidance off of 2016. It's adjusted for the FX and for the LOE assets. It suggests our underlying business will grow adjusted EBITDA in the low single-digits.

    下一張投影片(調整後 EBITDA 的橋接)採用相同方法,展示我們指引相對於 2016 年所暗示的調整後 EBITDA 成長。其已就匯率(FX)與 LOE 資產進行調整。這顯示我們的基礎業務將以低個位數成長調整後 EBITDA。

  • I want to point out that in 2017 we are making a number of investments that are incremental to our OpEx relative to the prior year and will not produce meaningful returns in 2017. Those include building the primary care salesforce for Xifaxan, investing incremental dollars in R&D, launching Siliq, relaunching Addyi, and building out our market access Managed Care team to support our current model. Again, these investments have the effect of reducing our near-term profitability by some $150 million in 2017, which reduces underlying adjusted EBITDA growth off of that adjusted for the LOE's and FX by some 420 basis points.

    我想指出,2017 年我們相較前一年在營運費用(OpEx)上進行了多項額外投資,而這些投資在 2017 年不會帶來顯著回報。其中包括:為 Xifaxan 建置基層醫療銷售團隊、在研發(R&D)上增加投入、推出 Siliq、重新上市 Addyi,以及擴編我們的市場准入(market access)與受管醫療(Managed Care)團隊以支援我們目前的模式。再次強調,這些投資使我們 2017 年的短期獲利能力約減少 1.5 億美元,並使在扣除 LOE 與匯率影響後的基礎調整後 EBITDA 成長率降低約 420 個基點。

  • So to repeat, our current guidance does not reflect the impact of any asset sales transactions that have not yet closed. When those transactions close we will update our guidance accordingly. We expect the sale of the consumer assets to L'Oreal to close in the near term and target mid-year for the closing of the Dendreon transaction. Next and very important, we expect to remain in compliance with the maintenance covenants contained in our credit agreement, both senior secured leverage and interest coverage throughout 2017.

    因此再重申一次,我們目前的指引未反映任何尚未完成交割的資產出售交易之影響。當這些交易完成交割後,我們將相應更新指引。我們預期將在近期完成把消費者資產出售給萊雅(L'Oreal)的交易,並以年中作為完成 Dendreon 交易交割的目標。接下來且非常重要的是,我們預期在 2017 年全年將持續符合信貸協議中的維持性財務約束條款(maintenance covenants),包括第一順位擔保槓桿比率與利息保障倍數。

  • Finally, we provide guidance for the full year. We do not and will not guide to quarters. However, we know that we live in a quarterly world, so let me talk about the phasing of our revenue and earnings.

    最後,我們提供的是全年指引。我們不會、也將不會提供季度指引。然而,我們知道市場以季度為單位運作,因此我來談談我們營收與獲利的分布節奏。

  • First, in 2016, our revenue and adjusted EBITDA were both skewed 49% for the first half and 51% for the second half. The first quarter is generally weaker for our Pharma businesses as patients are less likely to fill RX's until they satisfy their deductibles. It's also the quarter when Managed Care rebates and other programs that affect gross to net rise triggering increased accruals at the end of the quarter that are disproportionate to the increase in the rebates. Our first quarter of 2016 was our lightest revenue and adjusted EBITDA quarter.

    首先,在 2016 年,我們的營收與調整後 EBITDA 在上半年與下半年的分布分別為 49% 與 51%。對我們的製藥業務而言,第一季通常較弱,因為病患在達到自付額(deductibles)之前較不會去配領處方(RX)。此外,第一季也是受管醫療(Managed Care)回扣與其他影響毛額到淨額(gross to net)的方案上升的季度,這會在季末觸發較高的應計(accruals),其增幅往往不成比例地高於回扣本身的增加。我們 2016 年第一季是營收與調整後 EBITDA 最低的一季。

  • In 2017, we expect revenue to skew to the second half again with roughly 48% to 49% in the first half and that's the inverse being 51% to 52% in the second half for revenue. Adjusted EBITDA will be slightly more skewed then revenue as we are investment spending on a number of initiatives, the PCP salesforce, relaunching Addyi, launching Siliq, that are expected to begin to drive revenue in the second half but impact our EBITDA in the early part of the year.

    在 2017 年,我們預期營收仍將偏向下半年,上半年約占 48% 至 49%,相對地,下半年約占 51% 至 52%。調整後 EBITDA 的偏向程度將略高於營收,因為我們在多項計畫上投入支出——包括 PCP 銷售團隊、重新上市 Addyi、推出 Siliq——這些預期將在下半年開始帶動營收,但會在年初對 EBITDA 造成影響。

  • In 2017, we expect adjusted EBITDA to start low and end higher. That was a mouthful, but I hope the guidance information that we are providing is helpful to you as you think about our prospects for 2017 and well beyond. Let me turn it back to Joe.

    在 2017 年,我們預期調整後 EBITDA 將從較低水準開始,並在年底走高。內容有點多,但我希望我們提供的指引資訊能在你思考 2017 年以及更長遠的前景時有所幫助。我把時間交回給 Joe。

  • - Chairman & CEO

    - Chairman & CEO

  • Thank you, Paul, for a comprehensive review. Turning to slide 15, our dermatology business has a new leader, Bill Humphries, who joined us at the beginning of the year. Bill and the team have been working very hard to continue to build our reputation with dermatologists, podiatrists, payers and patients and to stabilize the dermatology market for us. Onexton TRx growth is accelerating and Jublia, our refill prescription growth is recovering. But we continue to expect volume pressure from higher co-pays and gross to net rebates in 2017.

    謝謝你,Paul,做了全面性的回顧。接著看第 15 張投影片,我們的皮膚科業務有了新的領導者 Bill Humphries,他在年初加入我們。Bill 與團隊一直非常努力,持續在皮膚科醫師、足病醫師、付款方與病患之間建立我們的聲譽,並為我們穩定皮膚科市場。Onexton 的 TRx 成長正在加速,而 Jublia 的續配處方成長正在回升。但我們仍預期 2017 年將面臨較高自付額(co-pays)以及毛額到淨額(gross to net)回扣所帶來的銷量壓力。

  • One of our goals for 2017 is to leverage our relationship with Walgreens. We are pleased with the recent progress with Walgreens during the past six months. We expect to launch a brand for generic pilot program with Walgreens later this year.

    我們在2017年的目標之一,是善用我們與Walgreens的合作關係。我們對過去六個月與Walgreens近期取得的進展感到滿意。我們預期將於今年稍晚與Walgreens推出一項學名藥試點計畫的品牌。

  • Moving to slide 16, our GI business. We are encouraged by the prescription trends we are seeing. In total, Xifaxan scripts were up 18% in 2016, Uceris was up 6%, Apriso was up 4%. Since we launched Oral Relistor at the end of the year, TRx's were up 13% in the fourth quarter. And we expect that this positive trend to continue. In addition, Relistor has greater than 80% of lives covered by commercial insurance.

    接著看第16頁,我們的腸胃(GI)業務。我們對目前看到的處方趨勢感到鼓舞。整體而言,2016年Xifaxan處方量增加18%,Uceris增加6%,Apriso增加4%。自我們在年底推出口服Relistor以來,第四季TRx增加13%。我們預期這項正向趨勢將持續。此外,Relistor在商業保險下的涵蓋人數(lives)覆蓋率超過80%。

  • Looking ahead to 2017, we are investing in a primary care salesforce expansion, launch of a nurse educator program, and expansion of the pain salesforce that we expect to further drive results in the GI business. We are also looking at new GI product development opportunities. For Xifaxan, we will initiate a next generation formulation and evaluate a potential oncology indication for Relistor.

    展望2017年,我們將投資於基層醫療銷售團隊擴編、推出護理師衛教計畫,以及擴充疼痛領域銷售團隊;我們預期這些將進一步帶動腸胃(GI)業務成果。我們也在評估新的GI產品開發機會。針對Xifaxan,我們將啟動下一代劑型開發,並評估Relistor在腫瘤適應症上的潛在用途。

  • Moving to slide 17, this slide shows the progress we have made in retaining our salesforce over the last four quarters. As you can see from the chart, early in 2016, our retention numbers were not where we wanted them to be, but turnover has stabilized over the past three quarters and at the end of the fourth quarter, our salesforce retention rate was approximately 94%. To be clear, there was some salesforce turnover in quarter one 2017, but this turnover is expected to launch of a new year and a new incentive time period. To be clear, I wanted to anticipate your questions, overall sales professionals promoting the GI business in Q1 2017 are up by 40%.

    接著看第17頁,本頁顯示我們在過去四個季度留任銷售團隊方面所取得的進展。如圖所示,2016年初我們的留任數據未達到期望,但過去三個季度離職率已趨於穩定,且在第四季末,我們的銷售團隊留任率約為94%。說清楚一點,2017年第一季確實有一些銷售團隊流動,但這種流動預期與新年度開始及新的獎酬期間啟動有關。同樣說清楚,我想先回應各位可能的問題:2017年第一季推廣GI業務的整體銷售專業人員人數增加了40%。

  • On to slide 18, will list the important investments we are making to drive growth across our businesses. First, let me provide additional details on our new primary care salesforce for Salix. As we announced in the press release yesterday, we have hired approximately 250 highly trained and experienced sales representatives and managers to bolster, create and sustain deep relationships with primary care physicians, who are key potential prescribers for Xifaxan and for Oral Relistor. Approximately 70% of the IBSD patients additionally present with symptoms to a primary care physician and we believe our efforts will enable us to reach physicians that account for nearly 75% of the primary care market opportunity.

    接著看第18頁,我們將列出為推動各項業務成長所進行的重要投資。首先,我補充說明我們為Salix建立的新基層醫療銷售團隊。如同我們昨天在新聞稿中宣布的,我們已聘用約250名受過高度訓練且具豐富經驗的業務代表與管理人員,以強化、建立並維繫與基層醫師的深度關係;這些醫師是Xifaxan與口服Relistor的關鍵潛在開立者。約有70%的IBSD患者也會因症狀而就診於基層醫師,我們相信這些努力將使我們能觸及涵蓋近75%基層醫療市場機會的醫師。

  • We have also expanded the number of dedicated pain sales representatives we have in the OIC market and established a nurse educator team to educate clinical staff. In dermatology, we are increasing our market access team to support Walgreens and the independent retailer model. At Bausch + Lomb, we are investing in contact lens manufacturing capabilities to yield improved capacity and cost per lens. We are also investing in research and development and increasing the investment in the pipeline by approximately 150 basis points over 2015. This is an important part of creating the new Valeant.

    我們也擴增了在OIC市場中專責疼痛領域的業務代表人數,並建立護理師衛教團隊以教育臨床人員。在皮膚科方面,我們正在擴大市場准入團隊,以支援Walgreens及獨立零售商模式。在Bausch + Lomb方面,我們投資於隱形眼鏡製造能力,以提升產能並降低每片鏡片成本。我們也投資於研發,並將相較2015年的管線投資提高約150個基點。這是打造「新Valeant」的重要一環。

  • We also evaluated the broader portfolio and identified several that I would refer to as hidden gems in the diversified products segment. These include Migranal, Diastat, and Zelapar. We are launching sales efforts to promote these under-appreciated assets and position them for future growth and success.

    我們也評估了更廣泛的產品組合,並在多元化產品部門中辨識出幾項我稱之為「隱藏寶石」的產品。其中包括Migranal、Diastat與Zelapar。我們正啟動銷售推廣工作,以推廣這些被低估的資產,並為其未來成長與成功做好定位。

  • Finally, in women's health, we are relaunching Addyi. We have recently collaborated with the American Sexual Health Association on an educational awareness campaign about female sexual difficulties called Find My Spark.

    最後,在女性健康方面,我們正重新推出Addyi。我們近期與美國性健康協會(American Sexual Health Association)合作,針對女性性困擾推出名為「Find My Spark」的教育宣導活動。

  • Turning now to the late stage pipeline on slide 19. As we have migrated to the new Valeant, we are investing more in research and development, quality and new product launches. R&D spend has also increased by 21% year over year. The increased spending has been productive. We are preparing to launch more than 50 new products in 2017, which we expect to drive approximately $100 million in annualized revenues. In the US, these products will include Bausch + Lomb Ultra for Presbyopia, Zen Scleral contact lenses and Addyi. We are also preparing for product launches in EMEA and Asia-Pacific regions.

    接著看第19頁的後期管線。隨著我們轉型為新Valeant,我們在研發、品質與新產品上市方面投入更多資源。研發支出也較去年同期增加21%。增加的支出已產生效益。我們正準備在2017年推出超過50項新產品,預期可帶來約1億美元的年化營收。在美國,這些產品將包括用於老花的Bausch + Lomb Ultra、Zen Scleral鞏膜隱形眼鏡以及Addyi。我們也正準備在EMEA與亞太地區進行產品上市。

  • Slide 20, lays out our expected R&D tablets in 2017, I think the slide does a good job of showing that we have active and productive R&D organization that is working to create innovative new solutions for patients and customers who rely on our products. First, we have a number of late phase projects. The group including a new Xifaxan formulation expected in the second half of 2017 and this may represent a more patient friendly formulation and break additional intellectual property protection.

    第20頁列出了我們在2017年預期的研發里程碑;我認為這張投影片很好地呈現出我們擁有一個活躍且具產出的研發組織,致力於為仰賴我們產品的病患與客戶創造創新解決方案。首先,我們有多個後期階段專案。其中包括預計於2017年下半年推出的新Xifaxan劑型;這可能代表更符合病患使用的劑型,並可延伸額外的智慧財產保護。

  • In another area, we're focused on submissions that we made in 2017, our important catalyst for our sales opportunities in 2018 and beyond. We anticipate a submission for Luminesse, our eye brightener product very soon. And IDP-118, a psoriasis product in the second half of 2017, we will plan to submit along with an acne lotion and another product for psoriasis IDP-122. As I briefly mentioned at the onset of the call, we are preparing for a number of product launches in the coming year including Stellaris in our surgical business, Vyzulta for Glaucoma in the second half of the year, Bausch + Lomb Ultra contacts, who are astigmatism and Siliq in the third quarter.

    在另一個面向,我們聚焦於2017年所進行的申報,這些將成為我們2018年及之後銷售機會的重要催化劑。我們預期很快將提交Luminesse(我們的眼部提亮產品)的申請。而IDP-118(乾癬產品)預計在2017年下半年提交;我們也計畫同時提交一款痤瘡乳液,以及另一款乾癬產品IDP-122。如同我在電話會議一開始簡要提到的,我們正為明年多項產品上市做準備,包括我們外科業務的Stellaris、下半年用於青光眼的Vyzulta、Bausch + Lomb Ultra隱形眼鏡(散光款),以及第三季的Siliq。

  • Slide 21 provides an update on Siliq or brodalumab, a treatment for psoriasis that was approved by the FDA on February 15, 2017. We are very pleased with this approval as psoriasis is a large and growing market. Just the US alone is estimated at approximately $7 billion for 2018. We expect to be a position launch Siliq later this year.

    第21頁提供Siliq(或brodalumab)的最新進展;這是一種治療乾癬的藥物,已於2017年2月15日獲FDA核准。我們對此核准感到非常滿意,因為乾癬是一個龐大且持續成長的市場。僅美國市場在2018年的規模估計約為70億美元。我們預期可在今年稍晚推出Siliq。

  • The reason we believe this product is an important advance in treating psoriasis and how it works, it's a receptor blocker. So, if you look at the diagram on slide 24, the other biologic products on the market operate higher up in the pathway. But when you actually can block the receptor, you may get a longer duration and a higher -- or a high percentage of efficacy. Now, I will point out the label includes a risk for suicide and suicide ideation. There is REMS program, but we believe this products represent a real opportunity to help patients with a rapid and durable efficacy.

    我們之所以認為這項產品是治療乾癬的重要進展,以及其作用機轉,在於它是一種受體阻斷劑。因此,如果你看第24頁的示意圖,市面上其他生物製劑多是在路徑上游發揮作用。但當你能直接阻斷受體時,可能帶來更長的作用持續時間,以及更高——或較高比例的療效。另外我要指出,標籤包含自殺與自殺意念的風險警語。本產品有REMS計畫,但我們相信這項產品提供了真正的機會,以快速且持久的療效幫助病患。

  • Moving on to slide 22, also in the treatment of psoriasis, we are working on a unique topical product that we are calling IDP-118. It's a combination of a steroid and a retinoid that may allow patients to use topicals for a longer time period. We have gotten positive results in the second Phase 3 trial. So, we're very excited about the prospect of bringing this product to the market for patients who utilize topicals for the treatment of psoriasis.

    接著看第22頁,同樣在乾癬治療方面,我們正在開發一款獨特的外用產品,稱為IDP-118。它是類固醇與維甲酸類(retinoid)的複方,可能讓病患能在更長期間使用外用治療。我們在第二項第三期試驗中取得正向結果。因此,我們對於將此產品帶給使用外用藥治療乾癬的病患之市場前景感到非常振奮。

  • On slide 23, I want to briefly mention latanoprostene bunod or Vyzulta, a novel monotherapy for the reduction of inter-occular pressure in glaucoma, a disease that affects approximately three million Americans and represents a $3 billion market opportunity. We have got a complete response letter late last year and refiled on Friday February, 24 with an opportunity for an approval later this year. We are working to get ourselves ready and prepared for a commercial launch later this year.

    在第 23 張投影片上,我想簡要提到 latanoprostene bunod(Vyzulta),這是一種用於降低青光眼眼內壓的創新單一療法。青光眼影響約三百萬名美國人,並代表約 30 億美元的市場機會。我們在去年年底收到一封完整回覆函(CRL),並已於 2 月 24 日(週五)重新遞交申請,有機會在今年稍晚獲得核准。我們正著手做好準備,以便在今年稍晚進行商業上市。

  • In summary, let's turn to slide number 24, this slide is how we are thinking about the Valeant turnaround. Last, are the steps we have taken to stabilize the business by delivering on our commitments. The middle column represents where we are now beginning the turnaround phase, which means executing on our plans. We'll do this by strengthening our balance sheet, focusing on specialty driven markets, markets that we believe have above average growth rates and our leadership position and pipeline. By allocating resources efficiently across this, we think we can maximize the opportunities in front of us.

    總結來說,讓我們看第 24 張投影片,這張投影片呈現我們如何思考 Valeant 的轉型復甦。最後一欄是我們為了履行承諾、穩定業務而採取的步驟。中間一欄代表我們現在開始進入轉型復甦階段,也就是執行我們的計畫。我們將透過強化資產負債表、聚焦專科驅動的市場來做到這點;這些市場我們認為具有高於平均的成長率,以及我們的領導地位與產品研發管線。透過在這些方面有效配置資源,我們認為可以把握並最大化眼前的機會。

  • Executing on these plans will be our focus over the next 2017 and 2018 time periods. We believe our team is well-positioned to execute in the year ahead. Looking to 2018 and beyond, our focus will be transforming the Company by innovating for the future, leading in our categories, launching more new products and balancing organic growth with inorganic growth as appropriate.

    在接下來的 2017 與 2018 期間,執行這些計畫將是我們的重點。我們相信團隊已具備在未來一年落實執行的良好條件。展望 2018 年及之後,我們的重點將是透過面向未來的創新來轉型公司、在各品類中保持領先、推出更多新產品,並在適當情況下平衡內生成長與外延式成長。

  • With that, operator, let's open up the line for questions.

    接下來,接線員,請開放電話線供提問。

  • Operator

    Operator

  • (Operator Instructions)

    (接線員指示)

  • Gregg Gilbert, Deutsche Bank.

    Gregg Gilbert,德意志銀行。

  • - Analyst

    - Analyst

  • Good morning, gentlemen. First, Paul, what can you say about your desire and your ability per market conditions to address your debt load in a bigger way that was not discussed, or beyond what was discussed in the prepared remarks? Secondly, can you paint us at least a preliminary picture of the potential for revenue and EBITDA growth in 2018 versus 2017, perhaps by framing LOEs that you can see, or any other color or hand signals, you're willing to offer? Thanks a lot.

    早安,各位先生。首先,Paul,依據市場狀況,你對於以更大幅度處理債務負擔(不論是未在會前講稿中提及的,或是超出已提及內容的)之意願與能力,有哪些可以分享?第二,你能否至少先初步描繪一下 2018 年相較 2017 年的營收與 EBITDA 成長潛力?例如從你們可見的專利到期(LOE)角度切入,或提供任何你願意給的補充資訊或暗示?非常感謝。

  • - CFO

    - CFO

  • Sure. Let me start with the debt question, I think I said in my prepared remarks, we look at the capital markets all the time for opportunities to improve both our financial and operating flexibility and also to extend maturities. I can assure everyone on the line this is something that myself and my Treasurer, Linda LaGorga and her team, we think about it every day.

    當然。我先從債務問題開始。我想我在會前講稿中提到,我們一直在關注資本市場,尋找能同時提升財務與營運彈性、並延長到期結構的機會。我可以向線上的各位保證,這是我本人以及我們的財務主管(Treasurer)Linda LaGorga 與她的團隊每天都在思考的事情。

  • We look out at 2018 and the maturities in 2018 and look out at 2020, certainly there are maturities in 2019 as well. Those are things that need to be addressed. I can't get specific or more specific with respect to timing or what we intend to do, but I can assure you that keeping an eye on the capital markets and moving quickly to address some of these issues is very high on our list.

    我們會檢視 2018 年的到期情況,也會看到 2020 年;當然 2019 年也有到期。這些都是需要處理的事項。我無法就時間點或我們打算採取的作法提供更具體的細節,但我可以向各位保證:密切關注資本市場並迅速採取行動來處理其中一些議題,是我們清單上非常優先的事項。

  • With respect to your question regarding 2018 versus 2017, I tried during my talk there with respect to guidance to frame some of the things that you needed to think about in 2018 that are different from what you see on the slide that shows the longer-term 2017 to 2020 CAGR rates for each one of our segments. For example, I called out the diversified segment specifically and said, based on the timing of the LOEs as we currently expect them in 2017, that segment will decline again -- higher than normal, or higher than average, by some 15% to 20% in 2017 versus 2016 before it moderates.

    至於你問的 2018 年相較 2017 年,我在談到財測指引時,嘗試說明一些你在 2018 年需要考量、且不同於那張顯示各事業部 2017 至 2020 年長期 CAGR 的投影片所呈現內容的因素。例如,我特別點出多元化事業部(diversified segment),並表示依我們目前對 2017 年 LOE 時點的預期,該事業部在 2017 年相較 2016 年將再次下滑——幅度高於正常或高於平均——約 15% 到 20%,之後才會趨緩。

  • I think you can do the math with respect to that slide that shows the longer-term CAGR to get an idea. That was the point of calling that out and I apologize that I rambled through a lot of information in a short period of time there. It will be on the transcript and it will be public and therefore something that we can help people with as we go forward here.

    我想你可以根據那張顯示長期 CAGR 的投影片自行推算,以取得概念。這就是我特別提出該點的原因;也抱歉我在短時間內講了很多資訊,顯得有些冗長。這些內容會出現在逐字稿中並公開,因此我們後續也能協助大家理解並持續追蹤。

  • The other area I called out specifically was within the Branded Rx, but that segment is dominated by the gastro business and by the dermatology business and called out that we expect that the derm business continues to need to be reset in 2017 as we completely shift to this new model, which features Walgreens and Managed Care and co-pay assistance [cards] and the like.

    我另外特別點出的領域是在處方品牌藥(Branded Rx)之內;但該事業部主要由腸胃(GI)業務與皮膚科業務主導。我也提到,我們預期皮膚科業務在 2017 年仍需要持續重整,因為我們正全面轉向這個新模式,其特點包括 Walgreens、受管理式醫療(Managed Care)、自付額補助(co-pay assistance)[卡]等。

  • As that completes, we will return that franchise to a growth mode but it won't be in 2017. So, that was the point of bringing that up. Then with respect to GI, indicated low single-digit growth in 2017 but higher single-digit growth thereafter. That should help you -- those are the major elements. We continue to believe that the B+ L business is a solid single-midget -- single-digit -- great one there -- single-digit grower over time if we care for it in the right way. I think that gives you enough to be able to model. Last thing -- sorry, last thing on B+ L, I also called out that the 2017 versus 2016 growth in B+ L is a little bit inflated because of the pipeline reductions that we saw in Eastern Europe during 2016.

    當這些調整完成後,我們會讓該產品線回到成長軌道,但不會是在 2017 年。所以我提出這點的用意在此。至於 GI,我們指出 2017 年為低個位數成長,但其後將是較高的個位數成長。這些應該能幫助你——這些是主要要素。我們仍然相信 B+L 業務長期而言是穩健的個位數——我剛剛口誤說成 single-midget——個位數成長者,只要我們以正確方式經營與照料它。我想這已足夠讓你建立模型。最後一點——抱歉,關於 B+L 的最後一點:我也提到,2017 年相較 2016 年 B+L 的成長率有些被墊高,原因是我們在 2016 年於東歐看到通路庫存(pipeline)下降所致。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Gregg, I simply refer -- Paul's comments are absolutely right and just refer you to page 14 in the presentation. It does look at some of the segment revenue growth expectations and some of the CAGRs on 2017 to 2020, in addition to the comments that Paul had, 4% to 6% on the Bausch + Lomb/International, the 8% to 10% on the Branded Rx, in terms of the CAGRs that we're thinking about.

    Gregg,我只是補充——Paul 的評論完全正確,也請你參考簡報第 14 頁。那裡確實列出一些事業部營收成長預期,以及 2017 至 2020 年的部分 CAGR;除了 Paul 的說明之外,我們目前思考的 CAGR 包括:Bausch + Lomb/International 為 4% 到 6%,Branded Rx 為 8% 到 10%。

  • - Analyst

    - Analyst

  • Sorry, guys, one nitpicky one on that, is the base year 2017 in that slide? Or is the base year 2016? Just so I am clear on that.

    抱歉,各位,我有個比較吹毛求疵的小問題:那張投影片的基期年度是 2017 年嗎?還是基期年度是 2016 年?我只是想確認清楚。

  • - CFO

    - CFO

  • It is 2017.

    是 2017 年。

  • - Analyst

    - Analyst

  • Okay. Thanks.

    好的。謝謝。

  • Operator

    Operator

  • Umer Raffat, Evercore ISI.

    Umer Raffat,Evercore ISI。

  • - Chairman & CEO

    - Chairman & CEO

  • Umer? Sounds like we may have lost Umer, so maybe we'll take the next question and come back to him if he is there.

    Umer?聽起來我們可能失去與 Umer 的連線了,所以也許我們先進行下一個問題,若他還在線上再回來。

  • Operator

    Operator

  • Louise Chen, Guggenheim.

    Louise Chen,Guggenheim。

  • - Analyst

    - Analyst

  • Thanks for taking my question. I noticed that there is an increasing number of organic new drug approvals and opportunities coming out of Valeant. So, just curious if you were thinking about R&D differently than you have historically? And, if so, what is your new go-forward R&D strategy? Thanks.

    謝謝讓我提問。我注意到 Valeant 近期有越來越多由內部研發帶來的新藥核准與機會。所以我想請教,你們是否正在以不同於以往的方式看待研發(R&D)?如果是的話,你們未來新的研發策略是什麼?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Certainly, Louise, it's an absolute comment about how we are viewing the new Valeant. As one can look at what we are investing in research and development. If you just look at the historical numbers, you can see that, 2016 versus 2015, we were up, if my recollection is about 21% incremental expenditures in research and development. So, we have had a good chance to look at the portfolio. Tage and our R&D leader has done a great job in working through a lot of the projects and looking at where we can go forward with new products that look at unmet medical needs.

    當然,Louise,這確實反映我們如何看待「新的 Valeant」。大家可以看看我們在研發上的投資。如果只看歷史數字,你會看到 2016 年相較 2015 年,我記得研發支出增加了大約 21%。因此,我們有很好的機會檢視整個產品組合。Tage 與我們的研發負責人做得非常出色,梳理了許多專案,並評估我們未來可推進的新產品方向,以滿足尚未被滿足的醫療需求。

  • Certainly, IDP-118 is just a simple example that previously has been more difficult for people to use a dermatology topical product for extended duration. Tage has come forward with a unique formulation that has the ability of putting together a retinoid plus a high-dose cortical steroid product and gives an opportunity, potentially, if approved by the FDA, to use a product for a longer duration going forward.

    當然,IDP-118 只是個簡單的例子;過去人們較難長期使用皮膚科外用產品。Tage 提出了一種獨特配方,能將維甲酸類(retinoid)與高劑量皮質類固醇產品結合在一起,並且在未來若獲 FDA 核准,可能讓產品得以更長期使用。

  • So that is just one example and, as we think about 2017, we're going to increase our expenditures one more time, continue to raise the incremental R&D expenditures to that $430 -- I'm sorry, $420 million to $435 million that Paul referenced in his comments. Yes, absolutely spending more behind it. Spending behind products that we think will make a big difference in patients lives and ultimately generate great returns for our shareholders. So, absolutely different approach.

    所以這只是一個例子;當我們思考 2017 年時,我們將再一次提高支出,持續把增量研發支出提高到 Paul 在評論中提到的 4.30 億美元——抱歉,是 4.20 億到 4.35 億美元。是的,絕對會在這方面投入更多。投入在我們認為能對病患生活帶來重大改變、並最終為股東創造優異回報的產品上。所以,確實是不同的做法。

  • - CFO

    - CFO

  • Yes, before we move on, Louise, I want to jump in on this as well, because R&D is a very important activity for us as we go forward. As you see, we are investing more in 2016. We are providing guidance and we're going to invest more in 2017. I will tell you that the realities of our capital structure causes us to invest less in R&D than we would like if we were less levered. So there is a bit of a challenge, but I can assure everybody that investment in R&D is a very high priority for us.

    是的,在我們繼續之前,Louise,我也想就此插一句,因為研發是我們未來非常重要的活動。如你所見,我們在 2016 年投入更多。我們也提供指引,並且將在 2017 年投入更多。我想說的是,我們資本結構的現實使得我們在研發上的投入比我們希望的要少;如果槓桿較低,我們會投入更多。所以確實有一些挑戰,但我可以向各位保證,研發投資對我們而言是非常高的優先事項。

  • I think after the third quarter people asked about things that we can do -- having higher earnings at the expense of R&D may, air quotes around that, may feel good in the short term but we need to invest those dollars in R&D to support not just our Branded Rx business but all of our businesses: our global eyecare business, our -- on and on. So, it is a balancing act. If we were less levered, we would invest more. We think we have good productivity and we are pretty focused on ensuring that we get maximum efficiency and productivity out of the dollars that we do commit there.

    我想在第三季之後,大家問到我們能做些什麼——以犧牲研發為代價來提高獲利(此處加上引號),短期內可能感覺不錯,但我們需要把這些資金投入研發,以支持不僅是我們的品牌處方藥業務,還有我們所有業務:我們的全球眼科護理業務,還有——等等。所以,這是一種平衡。如果我們的槓桿較低,我們會投入更多。我們認為我們的生產力不錯,也相當專注於確保我們在所承諾投入的資金上,取得最大的效率與生產力。

  • Operator

    Operator

  • Chris Schott, JPMorgan.

    JPMorgan 的 Chris Schott。

  • - Analyst

    - Analyst

  • Thanks very much for the questions. Just two here, first, can you just help us understand the 8% to 10% Branded Rx growth, as we think about the 2017 through 2020 in terms of pipeline versus core products? As I think about your business, you're still transitioning this year. I think as you mentioned, you have some LOEs on the derm side that you are facing in that time frame. So just elaborate a little bit, again, as we think about the core growth versus how much is relative for some of these pipeline opportunities in those longer-term targets?

    非常感謝讓我提問。我有兩個問題:第一,能否協助我們理解品牌處方藥(Branded Rx)8% 到 10% 的成長;當我們看 2017 到 2020 年時,這個成長在產品線(pipeline)與核心產品之間各占多少?就我對你們業務的理解,你們今年仍在轉型。我想如你提到的,在那段期間你們在皮膚科端仍面臨一些專利到期(LOE)。所以請再多談一點:在這些較長期目標中,核心成長相對於部分產品線機會的貢獻大概各是多少?

  • And the second question is on Siliq, I don't know if I'm pronouncing that one right. But now that you have the approval and label, can you just help us understand a little bit how you see differentiating this product from the two other IL-17s in the market? I realize it is a very large opportunity for the category as a whole, but when we think about the REMS and the black box you have, how do you see dealing with that relative to your competitors? Thanks very much.

    第二個問題是關於 Siliq,我不確定我是否念對。不過現在你們已取得核准與標籤,能否協助我們理解你們將如何把這個產品與市場上另外兩個 IL-17 產品做出差異化?我知道就整個類別而言這是非常大的機會,但當我們考量你們的 REMS 與黑框警語時,相較於競品,你們打算如何因應?非常感謝。

  • - Chairman & CEO

    - Chairman & CEO

  • So, I will start with your first one and then, Paul, jump in and then I will get to the Siliq question. And you did pronounce it correct. Thank you, Chris, for the correct pronunciation. Talking about -- looking at the revenue CAGR. The big part of what we are really looking at here is key product launches in 2017, 2018, 2019 and 2020. Now, admittedly some of our launches in the 2017 time frame, as Paul said, would be more second half weighted in terms of their activities.

    我先回答你的第一個問題,接著 Paul 補充,然後我再回答 Siliq 的問題。而且你念對了。謝謝你,Chris,發音正確。談到——看營收複合年成長率(CAGR)。我們在這裡真正關注的很大一部分,是 2017、2018、2019 與 2020 年的關鍵產品上市。當然,如 Paul 所說,我們在 2017 年時程的一些上市活動,會比較偏向下半年。

  • But looking at 2018 going forward, we have got the -- obviously, the full-year effect of brodalumab, the IDP-118, which is the retinoid and corticosteroid combination. We have got Vyzulta. We've got the EyeGate project. We've got a lot of different opportunities. We'll have the Luminesse product that I mentioned. So there's a lot of new product launch opportunities in 2018, that's going to help us with the -- some of the growth, specifically as we think about the future opportunities in derm.

    但從 2018 年往後看,我們將有——很明顯地,brodalumab 的全年效應、IDP-118(也就是維甲酸類與皮質類固醇的複方)。我們有 Vyzulta。我們有 EyeGate 專案。我們有很多不同的機會。我們也會有我提到的 Luminesse 產品。所以 2018 年有很多新產品上市機會,將幫助我們帶動——部分成長,特別是當我們思考皮膚科未來的機會時。

  • We also obviously are very excited about bringing in the primary care capability for Xifaxan and for Relistor. We think that's going to accelerate our ability to reach the physician's [group] for the IBS. So I think that's probably the two major points I'll talk about in terms of the launches and the incremental investment that Paul referenced in his comments.

    我們也顯然非常期待為 Xifaxan 與 Relistor 建立起基層醫療(primary care)的能力。我們認為這將加速我們觸及 IBS 醫師[群體]的能力。所以就上市與 Paul 在評論中提到的增量投資而言,我想這大概是我會談的兩個重點。

  • - Analyst

    - Analyst

  • Joe, could I just ask one quick question on derm, just quickly? If I think about derm prior to -- with the IL-17 and 118 launching. Should we think about the base derm business still declining beyond 2017? Or should we think about that as a business that can stabilize before we add in those new product launch opportunities?

    Joe,我能就皮膚科再快速問一個問題嗎?就很快。如果我思考在 IL-17 與 118 上市之前的皮膚科業務。我們是否應該認為皮膚科的基礎業務在 2017 年之後仍會下滑?或者應該把它視為一個在加入這些新產品上市機會之前就能先穩定下來的業務?

  • - Chairman & CEO

    - Chairman & CEO

  • We think that the total business is going to grow as we've said, of course. There is lots of exclusivity that we expect in that business in 2018, for example, there is some products like an Elidel that we may see some generic activity on, but absent that we think we will start to turn around. We have got a lot of confidence in our new -- Bill Humphries, our new leader in the business. That is really, I think probably the primary area I talk about.

    我們認為整體業務將如我們所說地成長,當然。我們預期該業務在 2018 年例如會有不少專屬性(exclusivity);有些產品像 Elidel,我們可能會看到一些學名藥動態,但若不考慮那些因素,我們認為我們將開始扭轉局面。我們對我們的新——Bill Humphries,我們在該業務的新領導人——非常有信心。我想這大概是我會談的主要部分。

  • Let me talk about Siliq and then I'll turn it to Paul. I think Siliq -- first and foremost, what we're most excited about with Siliq is that it represents a significant opportunity based on the efficacy data we have. As you know, these patients with psoriasis do have unmet clinical need for efficacy. We have, based on the clinical trials, significantly improved efficacy against -- in the clinical trials we tested it against the Stelara product, so we believe that increased clinical efficacy that we saw certainly versus Stelara is one core part of the question. I would also point out to you, though, that in the treatment of psoriasis, we know that there are other risks because some of the other products have other risks. There's a risk of cancer with some of the products. So there are other risks that other products have.

    我先談 Siliq,然後再交給 Paul。我認為 Siliq——首先也是最重要的,我們對 Siliq 最興奮的是,基於我們掌握的療效數據,它代表一個重大的機會。如你所知,這些乾癬患者在療效上確實存在未被滿足的臨床需求。根據臨床試驗,我們的療效有顯著提升——在臨床試驗中我們將其與 Stelara 產品做比較,因此我們相信我們所看到的、尤其相較 Stelara 的臨床療效提升,確實是問題的核心之一。不過我也要指出,在乾癬治療中,我們知道還存在其他風險,因為某些其他產品也有其他風險。有些產品有癌症風險。所以其他產品也有其風險。

  • And our view is that, for the appropriate patient, we believe that Siliq could represent a very important advance based on efficacy. The primary reason we believe that we're seeing the efficacy results is that we are a receptor blocker. In the use of pharmacological agents, when you can actually block the receptor, you tend to get a better -- a quicker response and also a response that is more durable because of the fact that you are actually blockading the receptor versus products that inhibit the pathways above the generation of the interleukin product -- the body can sometimes compensate for that.

    而我們的看法是,對於合適的患者,我們相信 Siliq 基於其療效,可能代表一項非常重要的進展。我們認為之所以看到這些療效結果,主要原因在於我們是受體阻斷劑(receptor blocker)。在使用藥理製劑時,當你能實際阻斷受體,通常會得到更好——更快的反應,且反應也更持久,因為你是在阻斷受體;相較之下,抑制白介素生成上游途徑的產品——身體有時會對此進行補償。

  • So we always believe, at least we always see, as an example of the treatment of hypertension in the angiotester receptor blockers had a much more profound impact on hypertension, as a simple example. We think that receptor blocker is the reason why we may have some be very -- able to help patients with psoriasis.

    所以我們一直相信,至少我們一直看到,以高血壓治療為例,血管張力素受體阻斷劑對高血壓有更深遠的影響,這只是個簡單例子。我們認為受體阻斷劑是原因,這也是為什麼我們可能在某些方面——能夠幫助乾癬患者。

  • - CFO

    - CFO

  • Yes, I think you covered it, Joe.

    是的,我想你已經涵蓋到了,Joe。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Umer Raffat, Evercore ISI.

    Umer Raffat,Evercore ISI。

  • - Analyst

    - Analyst

  • Thanks so much for taking my question. Sorry about the trouble with my headset. So, I just wanted to drill down the EBITDA a bit more. The guidance of $3.55 billion to $3.7 billion -- Paul, if I may, so divestiture is about $200 million on a pro-forma basis? Is that right? So, that is one part. The second part is, accounting changes -- what exactly is the delta from that, from year over year at? I realize PP&E step-ups are no longer in there. So, I just want to get to the pro-forma EBITDA assuming there were no accounting changes. And, then the third part of it is, the difference in definition versus covenant. I feel like if I could just get clarity on that -- that would be super helpful. Then finally, what exactly is the target for management's cash compensation that is tied to EBITDA? What is that target EBITDA number for the cash comp? Thank you.

    非常感謝讓我提問。抱歉我的耳機出了點狀況。所以,我只是想再更深入拆解一下 EBITDA。指引為 35.5 億美元到 37 億美元——Paul,如果我可以問一下,剝離(divestiture)在備考(pro-forma)基礎上大約是 2 億美元?對嗎?所以,這是一部分。第二部分是,會計變更——這部分的差異(delta)到底是多少,按年(year over year)來看?我知道 PP&E 的增值調整(step-ups)不再包含在內。所以,我只是想在假設沒有任何會計變更的情況下,推導出備考 EBITDA。然後第三部分是,定義與契約(covenant)之間的差異。我覺得如果我能把這點釐清——會非常有幫助。最後,管理層現金薪酬中與 EBITDA 掛鉤的目標到底是什麼?現金薪酬對應的目標 EBITDA 數字是多少?謝謝。

  • - CFO

    - CFO

  • Yes, let me start with the impact to the divestitures. This is based on if we close the consumer asset sale to L'Oreal here, call it, end of this month, or shortly, the impact on EBITDA would be about $70 million. If you close Dendreon midyear, it is about $65 million. That is on 2017. So I think that answers your question. With respect to the definition of adjusted EBITDA, as I said, we are trending towards a, I'll call it, middle of the fairway. I think that the items that we add back, and I did tick them off, are the ones that are most often used by companies in arriving at a definition of adjusted EBITDA. It is perhaps a little bit shrunk down from what we might have seen based on our prior definitions, but it is not hugely different.

    是的,我先從剝離的影響談起。這是基於我們若在本月底或不久之後完成將消費者資產出售給萊雅(L'Oreal)的交易,則對 EBITDA 的影響約為 7,000 萬美元。如果在年中完成 Dendreon 的交割,影響約為 6,500 萬美元。這是針對 2017 年。所以我想這回答了你的問題。至於調整後 EBITDA(adjusted EBITDA)的定義,如我所說,我們正趨向於——我稱之為——較為中性的標準。我認為我們加回(add back)的項目——我也逐一列舉了——是公司在得出調整後 EBITDA 定義時最常使用的那些項目。相較於我們先前的定義,可能略有收斂,但差異並不巨大。

  • I think what is really important, at least for us internally, is that we have implemented policies and procedures to ensure that any item that is going to be an add-back to arrive at an adjusted EBITDA is subject to a lot of scrutiny and importantly control. Not to say there wasn't before, but it is to say we put in place procedures that Joe is used to, I'm used to, Sam Eldessouky, who is our Chief Accounting Officer are used to, to maintain control over those items. The revised definition brings you very close to the definition that you would find in our credit agreement, very close.

    我認為真正重要的是,至少對我們內部而言,我們已實施政策與程序,以確保任何要作為加回項目、用以得出調整後 EBITDA 的項目,都會受到非常嚴格的審視,且更重要的是受到控管。並不是說以前沒有,但我們確實建立了 Joe 習慣的、我也習慣的,以及我們的首席會計官(Chief Accounting Officer)Sam Eldessouky 也習慣的程序,以維持對這些項目的控制。修訂後的定義讓你非常接近你會在我們信貸協議(credit agreement)中看到的定義,非常接近。

  • - Chairman & CEO

    - Chairman & CEO

  • Maybe just a final area that -- but I think Paul said everything, I agree with that. The only thing I'd say is, you asked a question about our management compensation. Well, I can't give you out exact numbers but I think it is very similar to the numbers that we were guiding to on revenue, they're a similar number or guiding to on EBITDA. Then of course one thing we have added this year, we will tell you more about it, is a return on capital metric for the long-term program. So those are the major areas in which management compensation would be based, return on tangible capital, return on capital that we will add.

    也許最後再補充一點——但我想 Paul 都說到了,我也同意。我唯一要說的是,你問到管理層薪酬。我無法給你確切數字,但我認為它與我們在營收指引上的數字非常相近,也與我們在 EBITDA 指引上的數字相近。當然,我們今年新增了一項,我們之後會提供更多資訊,就是長期計畫中的資本報酬率(return on capital)指標。所以管理層薪酬主要會基於這些領域:有形資本報酬率(return on tangible capital)、以及我們將加入的資本報酬率(return on capital)。

  • - Analyst

    - Analyst

  • Got it, Joe. Paul, just to be super clear, since investors are so laser focused on it, and investors care about $100 million or $200 million in EBITDA. The impact of accounting changes plus the delta versus the covenant, is that in the $100 million to $200 million range or not?

    了解了,Joe。Paul,為了非常清楚,因為投資人非常聚焦在這點,而且投資人很在意 EBITDA 的 1 億或 2 億美元。會計變更的影響加上相對於契約定義的差異,是否落在 1 億到 2 億美元的區間內,還是不是?

  • - CFO

    - CFO

  • Yes, I think what I said was our revised definition -- I wouldn't call it a material change to our EBITDA -- adjusted definition of adjusted EBITDA in accounts of adjusted EBITDA. The number there, as I said, if anything the number that you see is a closer representation of what you might be able to calculate for the credit agreement and with respect to those divestitures, when those occur first and foremost, the L'Oreal or the potential transaction with L'Oreal is certainly delevering. The transaction with Sanpower for Dendreon is what I would call from a fixed charge or interest coverage perspective broadly neutral, but also helpful to us with respect to the maintenance test on senior secured leverage.

    是的,我想我說的是,我們修訂後的定義——我不會稱之為對我們 EBITDA 有重大變動——也就是在帳務中調整後 EBITDA 的調整定義。如我所說,你看到的數字若有什麼不同,反而更接近你在信貸協議下可能計算出的結果;至於那些剝離交易,一旦發生,首先,萊雅(L'Oreal)或與萊雅的潛在交易,確實是在去槓桿(delevering)。而與三胞(Sanpower)就 Dendreon 的交易,從固定費用或利息保障倍數(interest coverage)的角度來看,我會稱之為大致中性,但同時也有助於我們在第一順位擔保槓桿(senior secured leverage)的維持性測試(maintenance test)。

  • - Analyst

    - Analyst

  • Got it.

    了解。

  • - CFO

    - CFO

  • Let me restate what I think was an important point in my prepared remarks. Based on our plan, we expect to be in compliance with the terms of our credit agreement throughout 2017. I think we, internally-- and I know that it is not possible for external parties to have access to all of the data that we have access to, nor is it easy for you to calculate, even if you have the credit agreement in hand, the exact numbers but we obviously do that work and what we are saying is, based on our plan, we expect to be in compliance with the maintenance covenants contained in our credit agreement throughout 2017.

    讓我重申我在事先準備的發言中我認為很重要的一點。根據我們的計畫,我們預期在 2017 年全年都能符合我們信貸協議條款。我想我們在內部——而且我知道外部人士不可能取得我們能取得的所有資料,即使你手上有信貸協議,也不容易計算出精確數字——但我們顯然會做這些工作;我們所說的是,根據我們的計畫,我們預期在 2017 年全年都能符合信貸協議中所包含的維持性契約(maintenance covenants)。

  • One last thing as long as I've got the floor and you're focused on debt. When people look at interest -- and I do call out for you the guidance for 2017 interest, we broke it apart into cash -- the cash interest and the amortization of deferred finance costs. That is an important number for looking at cash coverage. What is also not as obvious is that the terms of our credit agreement when we prepay debt, or repay debt, we adjust the PTM interest cost, cash interest cost, to reflect the payment of that debt. So there are not obvious to a third party or easily calculable benefits associated with our using our free cash flow to retire debt associated with us making divestitures even of relatively modest assets that improve our credit position. I will stop there.

    最後一點,既然我還在發言而且你們聚焦在債務上。當人們看利息——我也特別為你們指出 2017 年利息指引,我們把它拆成現金——現金利息,以及遞延融資成本的攤銷。這是用來看現金保障能力(cash coverage)的重要數字。另外一個不那麼明顯的是,依照我們信貸協議的條款,當我們提前償還(prepay)或償還(repay)債務時,我們會調整 PTM 利息成本、現金利息成本,以反映該筆債務的償付。因此,對第三方而言,與我們運用自由現金流(free cash flow)來清償債務、以及我們透過出售即便相對規模不大的資產來改善信用狀況相關的效益,並不明顯或不易計算。我就說到這裡。

  • Operator

    Operator

  • David Risinger, Morgan Stanley.

    David Risinger,摩根士丹利(Morgan Stanley)。

  • - Analyst

    - Analyst

  • I have a couple questions. First, with respect to the franchises that are going generic in 2017 or facing significant decline, it seems like you are giving guidance that is too low, Paul, because Nitropress only has one generic competitor and Isuprel has none. And it seems like the collapse that you are forecasting is actually too severe for 2017. So I just wanted to get some more color on whether you think that is the right guidance to be that low given the lack of competition to some of these products currently.

    我有幾個問題。第一,關於 2017 年將面臨學名藥化(going generic)或顯著下滑的產品線(franchises),Paul,你給的指引看起來太低了,因為 Nitropress 只有一家學名藥競爭者,而 Isuprel 則沒有。而且你所預測的崩跌幅度,對 2017 年而言似乎過於嚴重。所以我想多了解一些,你是否認為在目前部分產品缺乏競爭的情況下,把指引訂得這麼低是合理的。

  • And then, second, with respect to Vyzulta, can you just update us on the launch timing? I thought that last year you had suggested it might be in the second quarter, but I am not sure when you are thinking about being able to launch that this year. And just confirm that, that is going to be recorded as revenue in the Brand Rx and not be Bausch segment, even though the Bausch salesforce will be selling it. And then, finally, if you could just update us on the Xifaxan patent litigation developments to watch ahead. Thanks so much.

    第二,關於 Vyzulta,你能否更新一下上市(launch)時程?我記得去年你曾暗示可能在第二季,但我不確定你們今年預計何時能夠推出。也請確認一下,該產品將會在 Brand Rx 中認列為營收,而不是歸在 Bausch 部門,儘管會由 Bausch 的銷售團隊來銷售。最後,如果你能更新一下 Xifaxan 專利訴訟(patent litigation)後續值得關注的進展。非常感謝。

  • - CFO

    - CFO

  • Yes, sure. Let me start, it's Paul, Let me start with a discussion on rounding what I'll call the LOE assets. And you can refer to the detailed chart that we posted on our website. You bring up a couple of good points, David. But let me be clear that we believe that in 2017 we will face loss of exclusivity for the products on that list that are not already generic. We have made assumptions with respect to the timing, with respect to the number of entrants, and with respect with the way that market plays out in the wake of the entrance of either one or more parties to compete with the assets.

    是的,當然。我先開始,我是Paul。我先就我所稱的LOE資產(專利到期/失去獨占性資產)的取整(rounding)做一些說明。你可以參考我們在網站上發布的詳細圖表。David,你提出了幾個很好的觀點。但我要說清楚的是,我們相信在2017年,對於那份清單上目前尚未成為學名藥的產品,我們將面臨失去獨占性。我們已就時點、進入者數量,以及在一個或多個競爭者進入後市場如何演變,做出了相關假設。

  • I want to be super clear here:, we hope because it would be more cash to us, that we are being overly conservative here. I don't believe we're being overly conservative but that we are being conservative here with respect to the impact on 2017 from that basket of assets. When providing guidance -- I say this a lot, we think of guidance as a commitment. When providing guidance, us assuming good things with respect to that portfolio would feel better at the time of the provisional guidance but would be not well received if it turned out that it played out in a more conservative or in a more deleterious manner with respect to our products.

    我想在這裡非常清楚地說:我們希望(因為那會帶來更多現金流入我們),我們在這裡是過度保守的。我不認為我們是過度保守,但我認為就那一籃子資產對2017年的影響而言,我們採取了保守的假設。在提供指引時——我常這麼說——我們把指引視為一種承諾。在提供指引時,如果我們對該投資組合假設較多正面情境,當下的初步指引可能會讓人感覺更好,但若結果以更保守或對我們產品更不利的方式發展,市場的反應就不會好。

  • So, is it conservative? Yes, it's skewed towards the conservative side. We provided everybody with the information where you can sit down and look and say, based on our assumed date of entry if you have information or you believe you have information that is better than our market intel or different than our market intel, everybody can come to a point of view, but here comes the important point. That bucket or basket of LOE assets is viewed by us as a potential basket of future cash flows.

    所以,這是保守的嗎?是的,它偏向保守的一側。我們已向大家提供資訊,你們可以坐下來檢視並說:基於我們假設的進入日期,如果你有資訊、或你相信你掌握的資訊比我們的市場情報更好或不同,每個人都可以形成自己的觀點——但重點來了。那一桶或那一籃LOE資產,在我們看來是一籃子潛在的未來現金流。

  • We hope it is as big as it can possibly be, but from an earnings perspective, if our earnings from that LOE bucket turn out to be better in 2017, that will be great because of the cash it will generate, which we will use to reduce debt. But from a go-forward earnings basis, this is a bucket that is only going to do one thing and that is decline, whether that is per the schedule that we have included in our guidance or whether that is at some lesser decline rate.

    我們希望它能盡可能大,但從獲利角度來看,如果我們來自那個LOE桶的2017年獲利結果比預期更好,那會很棒,因為它會帶來現金,而我們會用這些現金來降低負債。但從未來的獲利基礎來看,這一桶資產只會有一件事發生,那就是下滑——不論是依照我們在指引中納入的時程下滑,或是以較小的下滑幅度下滑。

  • If it is lesser, what it's going to do, it's going to create a growth hold, if you will, for 2018 versus 2017, because those assets will be in our earnings. So, I'm quite long winded there, but I think a very important point, the way we think about that basket of assets. I hope we do a whole lot better with all of those assets. But we're not going to bet on it. We're certainly not going to use a more aggressive forecast in providing guidance to the Street. Joe?

    如果下滑幅度較小,它會在2018年相對於2017年形成一個成長的「緩衝/支撐」(growth hold),因為那些資產仍會反映在我們的獲利中。所以我講得有點長,但我認為這是非常重要的一點:我們如何看待那一籃子資產。我希望我們在所有這些資產上的表現都能好很多。但我們不會把它當作賭注。我們當然也不會在向華爾街提供指引時使用更激進的預測。Joe?

  • - Chairman & CEO

    - Chairman & CEO

  • I think maybe I agree with everything Paul said. I think what we try to do is be as transparent as possible. We put our assumptions there, and if you have a different view, we understand it but certainly want to just try to provide the transparency, as Paul said, just to be as conservative so that we think going forward we don't have any negative surprises.

    我想我大概同意Paul說的每一點。我認為我們努力做到的是盡可能透明。我們把假設放在那裡,如果你有不同看法,我們理解,但我們確實只是想提供透明度;如Paul所說,就是要保持保守,讓我們認為未來不會出現任何負面意外。

  • On the question of the Vyzulta, one thing I'll say it's a name that we are provisionally using. We're awaiting the final approval on that, but we do think that, that's a opportunity for us to launch. We think right now the best time we should say is a third-quarter 2017 launch is the best assumption there, based on the status with the FDA in reinspecting our facility. I think you asked one last question on the Xifaxan and the ANDA that was filed against it in 2016.

    關於Vyzulta的問題,我要說的一點是:這個名稱是我們暫時使用的。我們正在等待最終核准,但我們確實認為那是我們推出上市的一個機會。以目前情況來看,基於FDA正在對我們的設施進行複查(reinspecting)的進度,我們認為最好的假設是2017年第三季上市。我想你最後還問了一個關於Xifaxan以及2016年針對它提交的ANDA(簡化新藥申請)的問題。

  • We don't want to comment on any ongoing litigation but we do expect -- the only thing I will say is we do expect a trial in 2018 on that. Obviously we think we've got very strong intellectual property on the product. Our patents run through 2029 so we feel very good about the number of patents we have relative to the intellectual property associated with the product.

    我們不想評論任何正在進行的訴訟,但我們預期——我唯一能說的是——我們預期在2018年就此進行審判。顯然我們認為我們在該產品上擁有非常強的智慧財產權。我們的專利有效期到2029年,因此就與該產品相關的智慧財產權而言,我們對我們擁有的專利數量感到非常有信心。

  • - Analyst

    - Analyst

  • Great. Thanks so much.

    很好。非常感謝。

  • Operator

    Operator

  • Annabel Samimy, Stifel.

    Annabel Samimy,Stifel。

  • - Analyst

    - Analyst

  • Thanks for all the information you have given us to figure out the cash flow, but I just want to see if we can be a little bit more simple about this. If you take the EBITDA number that you have given us, you'd strip out the $135 million EBITDA impact you expect to have from divestitures and you go through these calculations, I guess the question comes to a very simple question: how much debt have you already paid down to achieve the $5 billion target that you have? How much cash flow will you have? And how much more divestiture do you need to do to be able to meet that $5 billion target?

    感謝你們提供所有資訊讓我們推算現金流,但我只是想看看我們能不能把這件事簡化一點。如果你採用你們提供的EBITDA數字,把你們預期因資產剝離而造成的1.35億美元EBITDA影響扣除,再做完這些計算,我想問題就變成一個非常簡單的問題:為了達成你們提出的50億美元目標,你們到目前為止已經償還了多少債務?你們會有多少現金流?以及你們還需要再做多少資產剝離,才能達到那個50億美元目標?

  • That's my first question, because we are drowning in a lot of these numbers but I think it is a very simple answer that we are looking for. And then going back to the brodalumab or the Siliq differentiation, there is another IL-17A receptor out there. The efficacy seems somewhat comparable to Siliq. I just want to know how you are going to differentiate it when it has its own suicidality black box warning on it. Is the certification process too onerous for physicians to adopt it? Can you just talk to us about how you think this is going to play out with regard to the competitive products out there that are similar mechanisms? Thanks.

    這是我的第一個問題,因為我們被很多數字淹沒了,但我認為我們要找的是一個非常簡單的答案。然後回到brodalumab或Siliq的差異化,市場上還有另一個IL-17A受體的產品。其療效看起來與Siliq有些相近。我只是想知道,當它本身也有自殺傾向的黑框警語時,你們要如何做出差異化。認證流程是否對醫師採用而言太過繁瑣?你們能否談談,面對外部具有相似作用機轉的競品,你們認為競爭態勢會如何發展?謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Let me just start with the big picture on the cash flow and the debt repayment and then, Paul, you can please add to that. Then I'll address the brodalumab competitor question. On the question of the cash flow and what we've paid down and what we haven't paid down, just to be 100% clear, the numbers that we pay down, in permanent debt in 2016 was the $1.84 billion which was ahead of our permanent debt payment that we committed to $1.7 billion. We did $1.84 billion. When it comes to the actual total debt repayment that occurred in 2016, it was approximately $1.2 billion. So there was some increase in short-term debt. So $1.2 billion I think is what Paul referenced.

    我先從現金流與償債的大方向開始說明,然後Paul你也可以補充。接著我會回答關於brodalumab競品的問題。關於現金流以及我們已償還與未償還的部分,為了百分之百清楚:我們在2016年償還的永久性債務(permanent debt)金額是18.4億美元,這高於我們承諾的17億美元永久性債務償還額。我們做到了18.4億美元。至於2016年實際發生的總債務償還金額,大約是12億美元。因此短期債務有一些增加。所以我認為Paul提到的是12億美元。

  • On the question of the incremental amount of major asset sales that we have, we have not closed, as Paul said, the CeraVe transaction, or the skincare transaction, that was a $1.03 billion of proceeds. And we have obviously not closed the Dendreon transaction, which we expect Dendreon to close sometime in the -- I think we said the second half of 2017.

    關於我們尚未完成交割的重大資產出售增量部分,如Paul所說,我們尚未完成CeraVe交易(或護膚品交易)的交割,該交易帶來10.3億美元的處分所得。而且我們顯然也尚未完成Dendreon交易的交割;我們預期Dendreon會在——我想我們說過——2017年下半年某個時間完成交割。

  • Now, those together generate proceeds of approximately $2.1 billion -- $2.19 billion to be clear. That is approximately the numbers that we will have available. There are some transaction expenses, taxes, et cetera, but those are not going to be a major component that comes off of that. So, that $2.1 billion, if I could just round that, would be the basis for the ability for us to pay down debt in 2017. Paul, is there anything you wanted to add to try to answer the rest of Annabel's question and then I will come back on the brodalumab?

    現在,這些合計產生約 21 億美元的處分所得——更精確地說是 21.9 億美元。這大約就是我們可動用的金額。會有一些交易費用、稅金等等,但從中扣除的比例不會是主要部分。因此,若我把這 21 億美元四捨五入,這將成為我們在 2017 年償還債務能力的基礎。Paul,你是否想補充一下以回答 Annabel 其餘的問題?然後我會再回到 brodalumab 的部分。

  • - CFO

    - CFO

  • Yes, sure. On the progress against the $5 billion target -- and Joe covered this but I will give it as simply as I can. Before the two remaining assets sales are on the table, Dendreon and the consumer products to L'Oreal, we paid off about $1 billion of debt. Those two -- the proceeds from those will actually be a little bit less than $1.3 billion plus $0.8 billion. We have to withhold some taxes or I should say pay some taxes. We will get them back but not right away at closing. So, we expect to have proceeds from those two transactions over the course of the next, call it, six months of about $1.9 billion.

    好的,當然。關於朝 50 億美元目標的進展——Joe 已經提過了,但我會盡量用最簡單的方式說明。在剩下兩項資產出售(Dendreon 以及將消費性產品出售給萊雅 L'Oreal)尚未納入之前,我們已償還了約 10 億美元的債務。那兩項——其處分所得實際上會略低於 13 億美元加上 8 億美元。我們必須預扣一些稅款,或者說需要先繳一些稅。我們會拿回來,但在交割時不會立刻返還。因此,我們預期在接下來大約六個月內,這兩筆交易合計可帶來約 19 億美元的處分所得。

  • Then in six months to get to Dendreon, we expect to close the L'Oreal transaction shortly. So in the aggregate it's about $2.9 billion towards the $3 [billion] goal. We obviously continue to use free cash flow from our business to reduce debt. We would expect to continue to look at additional asset sales, particularly of non-core businesses, in order to be able to meet that $5 billion number by Q1 of 2018.

    接著在六個月內、直到 Dendreon 交割,我們預期萊雅(L'Oreal)交易將很快完成。所以合計約為 29 億美元,朝 30 億美元目標邁進。我們顯然也會持續運用本業的自由現金流來降低負債。我們預期也會持續尋找額外的資產出售機會,特別是非核心業務,以便在 2018 年第一季前達成 50 億美元的目標。

  • - Chairman & CEO

    - Chairman & CEO

  • Then on your question of Siliq and our positioning. We recognized our label includes a suicide ideation warning and we will have (inaudible) you're absolutely right. But we also recognize that we have great efficacy and one of the things that, if you talk to patients, which we have done a lot of lately, we think the positioning opportunity is really going to be on the efficacy side of the equation and how this product can make a difference. Unfortunately psoriasis patients don't all respond to the same products. So we think just bringing forth a new product will be an opportunity to help some patients that are not getting relief now.

    接著是你關於 Siliq 以及我們定位的問題。我們知道我們的標籤包含自殺意念警語,而且我們會有(聽不清楚),你說得完全正確。但我們也認知到我們具有很好的療效;而且其中一點是,如果你和病患交流——我們最近做了很多——我們認為定位機會將主要在於療效面,以及這個產品如何帶來改變。不幸的是,乾癬病患並非都對相同產品有反應。因此我們認為推出一個新產品,將有機會幫助一些目前仍未獲得緩解的病患。

  • As I said, the only other thing I will comment is by having a receptor blocker, because you're actually blocking the receptor, it does have the potential for a long duration and a rapid onset of efficacy because of the way the mechanism works with the receptor blocker versus any product that inhibits the pathway for the interleukin factor. To me it is the receptor blocker -- is really the primary potential differentiation and what it potentially means for both the duration of activity and the rapid onset of activity.

    如我所說,我唯一想補充的是:由於它是受體阻斷劑,因為你實際上是在阻斷受體,依其作用機轉,相較於任何抑制白介素因子路徑的產品,它可能具有作用持續時間長以及起效快速的潛力。對我而言,受體阻斷劑——才是真正主要的潛在差異化所在,以及它對於作用持續時間與快速起效可能代表的意義。

  • - Analyst

    - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • - CFO

    - CFO

  • Before you click off, Annabel, you made that comment, drowning in numbers. I hope we have not provided too much information that it somehow makes us difficult to follow. I think the intention was certainly to provide transparency, to provide lots of information, and context for people to develop models. We understand that it was a lot that we put out here this morning.

    Annabel,在你掛線之前,你提到「被數字淹沒」。我希望我們沒有提供過多資訊,以致於讓大家難以跟上。我想我們的用意確實是提供透明度、提供大量資訊,以及讓大家建立模型所需的背景脈絡。我們理解今天早上我們釋出的內容很多。

  • I would expect that, as people look through that information, particularly folks on the sell side but buy side as well, we will have questions with respect to that information. By putting all this information out there under Reg FD, it enables Joe, myself, Scott, and others to have discussions about the information we provided. So, again, the intention was not to just throw a lot of information out at the market. The intention was to provide you with information that improves your ability to measure how we are doing.

    我預期當大家檢視這些資訊時,特別是賣方,但買方也一樣,會就這些資訊提出問題。在 Reg FD 的規範下把這些資訊公開,使得 Joe、我、Scott 以及其他人能就我們提供的資訊進行討論。所以,再次強調,我們的目的不是只是把大量資訊丟給市場。我們的目的,是提供能提升你衡量我們表現能力的資訊。

  • - Chairman & CEO

    - Chairman & CEO

  • And transparency. That's what we want to be, is very transparent as we form the new Valeant.

    以及透明度。這就是我們想成為的樣子——在打造新的 Valeant 時,保持高度透明。

  • - Analyst

    - Analyst

  • Thank you.

    謝謝。

  • Operator

    Operator

  • Gary Nachman, BMO Capital Markets.

    BMO Capital Markets 的 Gary Nachman。

  • - Analyst

    - Analyst

  • How far along are you with divesting other assets besides the ones you announced? Are you still anticipating similar type multiples that you had indicated previously? And have you changed your view of what is non-core in terms of geography and therapeutic area?

    除了你們已宣布的資產之外,你們在剝離其他資產方面進展到什麼程度?你們是否仍預期會有與先前所提到相似類型的估值倍數?以及你們是否改變了對於「非核心」的看法(就地理區域與治療領域而言)?

  • And then, in terms of the target growth rates of the core businesses, how much -- that you guys have been talking about, how much of that is price versus volume? It seems like you still have been taking a bunch of price increases even if they all fall below 10%.

    另外,就核心業務的目標成長率而言——你們一直在談的那個——其中有多少來自價格、多少來自銷量?看起來你們仍然進行了不少漲價,即使都低於 10%。

  • - Chairman & CEO

    - Chairman & CEO

  • All right. Let me start with the first question. First of all, where are we with the processes? We do have additional processes underway, so, yes, there are some additional processes underway. We do have a very active process for a number of the assets. Relative to the first part of your question also was what's core, what's non-core. We have not changed our definition. Core for us still is what we referred to as three potential core areas: number one is the Bausch + Lomb business and how that represents the eyecare growth opportunity; number two, it is the GI business; and number three is our dermatology business.

    好。我先從第一個問題開始。首先,我們的流程進展到哪裡?我們確實還有其他流程在進行中,所以,是的,還有一些額外的流程正在推進。針對多項資產,我們有非常積極的流程在運作。至於你問題的第一部分也包括什麼是核心、什麼是非核心。我們沒有改變我們的定義。對我們而言,核心仍是我們所稱的三個潛在核心領域:第一是 Bausch + Lomb 業務,以及它所代表的眼科照護成長機會;第二是 GI(腸胃)業務;第三是我們的皮膚科業務。

  • We have also supplemented core versus non-core by looking at geography. The US and Canada are strong geographies for us and represent a very important core. There are some geographies in the world that are not core. For example, that's why one of things we did was divest the business in Vietnam and Indonesia, it just wasn't a core for us. We felt by reducing complexity, we can help simplify the business model and get the focus on, really, where we can really grow for the business for the future. On the next part of your question --

    我們也透過地理區域來補充核心與非核心的判斷。美國與加拿大對我們而言是強勢地區,並構成非常重要的核心。全球有些地區並非核心。例如,這就是我們剝離越南與印尼業務的原因之一,因為那對我們而言並非核心。我們認為透過降低複雜度,可以協助簡化商業模式,並把焦點放在——真正能讓我們在未來成長的地方。關於你問題的下一部分——

  • - Analyst

    - Analyst

  • Actually, Joe, before you move on, just in terms of the multiples that you are seeing I guess with the assets, could you just comment on that versus the types of targets that used to run out there previously, sort of on a broad level?

    其實,Joe,在你繼續之前,就你看到的資產估值倍數而言,你能否就此做個評論,和先前市場上常提到的那些目標相比,大致上是怎麼樣?

  • - Chairman & CEO

    - Chairman & CEO

  • See, I think, what we originally said is that -- a couple comments, we said number one we said that we would expect to pay down $5 billion of debt, both from asset sales as well as our operational results and we saved by that one. The other thing we talked about is that we identified what we refer to as $2 billion of revenue for what I would refer to as non-core. We think that those can generate somewhere in the $8 billion of proceeds but I think really we're not trying to suggest every one of those is going to get sold.

    你看,我認為我們最初說的是——我有幾點要說:第一,我們說過我們預期要償還 50 億美元的債務,來源包括資產出售以及我們的營運成果,而我們也確實遵守了這一點。另一件我們談到的是,我們辨識出我們所稱約 20 億美元營收、我會稱之為非核心的部分。我們認為那些可能產生約 80 億美元的處分所得,但我想我們並不是要暗示其中每一項都會被出售。

  • We just really trying to use that as illustrative opportunity to identify non-core asset sales that we think are going to help us to pay down and reach this $5 billion of debt repayment. I don't see major changes just from, as a general comment, in how we are looking at potential asset sales. If you think about what we have sold so far, I think the range has been anywhere from -- for the larger ones, anywhere from about 7 plus to 20 plus EBITDA range if you think about what we have sold so far. There was another question on the pricing, Paul, do you want to take that one?

    我們只是想把它作為一個示意性的機會,用來辨識我們認為能協助我們償還並達成這 50 億美元債務償還目標的非核心資產出售。就一般性評論而言,我沒有看到我們在看待潛在資產出售的方式上有重大改變。如果你看我們迄今賣掉的資產,我認為區間大概是——以較大型的來說,約在 7 倍以上到 20 倍以上的 EBITDA 倍數範圍內(以我們迄今出售的項目來看)。另外還有一個關於定價的問題,Paul,你要回答那個嗎?

  • - CFO

    - CFO

  • Yes, sure. I think embedded in the 2017 guidance and 2018 and beyond in those CAGRs is an expectation that we can get low-to-mid single-digit price increases, those are net, across our portfolio as we go out. Now, it is not always the same, I use as the example 2017 versus 2016, the impact of price -- the fundamental improvement in our business, exclude the LOEs. You are getting maybe 100 basis points of lift on the overall portfolio, but we expect in latter years, we will be able to get a little bit better than that.

    是的,當然。我認為在 2017 年的指引,以及 2018 年及之後那些 CAGR(複合年成長率)中,已經內含一個預期:隨著時間推進,我們在整體產品組合上可以取得低到中個位數的淨價格上調。不過,這並不總是相同;我以 2017 年對比 2016 年為例,價格的影響——也就是我們業務的基本面改善(不含 LOE)。你可能會在整體產品組合上獲得約 100 個基點的提升,但我們預期在後續年度,我們能做到比這再好一些。

  • - Analyst

    - Analyst

  • Okay. Thank you.

    好的。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Gary, one other question I think you had, or part of it, you asked a question about how we're relying on it. One of the important things I want to make sure is clear is that if you think about our Bausch + Lomb business and how much of our businesses is not dependent on US pricing. It's our Asia business for example, our European business, our Bausch + Lomb business, certainly the contact lens business, there's a significant part of our business that is not dependent upon the US-based pricing system.

    Gary,你還有另一個問題,我想你有提到,或其中一部分,你問到我們如何依賴它。我想要確保一點很清楚:如果你看我們的 Bausch + Lomb 業務,以及我們有多少業務並不依賴美國定價。例如我們的亞洲業務、歐洲業務、我們的 Bausch + Lomb 業務,當然還有隱形眼鏡業務;我們有相當大一部分業務並不依賴以美國為基礎的定價體系。

  • Operator

    Operator

  • Douglas Tsao, Barclays.

    Douglas Tsao,Barclays。

  • - Analyst

    - Analyst

  • Thanks for taking the questions. Just a couple quick ones. First of all, Paul, if maybe you could provide some commentary in terms of the progress that you saw from the Walgreens business in terms of ASPs. I think you said there was some further improvement. I know there was a pretty sharp improvement in the third quarter versus the first half of the year. How much more room do you think there is? Or should we -- has that sort of been optimized?

    謝謝讓我提問。我有幾個很快的問題。首先,Paul,或許你可以就 Walgreens 業務在 ASP(平均銷售價格)方面的進展提供一些評論。我想你說還有一些進一步改善。我知道第三季相較於上半年有相當明顯的改善。你覺得還有多少改善空間?或者我們是否——那已經算是最佳化了?

  • And then, second, in terms of the impact of the LOEs, maybe I missed it, but I think you talked about in the slides $715 million impact in 2017 but obviously there is some contribution in the year, I think it was around $235 million. So should we think about the full-year run-rate impact as $945 million? Is that the right way to think about it?

    第二,關於 LOE 的影響,也許我漏聽了,但我想你在投影片中提到 2017 年影響為 7.15 億美元,但顯然當年度仍有一些貢獻,我想大約是 2.35 億美元。所以我們是否應該把全年 run-rate(年化)影響視為 9.45 億美元?這樣理解對嗎?

  • - Chairman & CEO

    - Chairman & CEO

  • Let me get the Walgreens question and then I will give it to Paul for the second part of that question. On the Walgreens question, in terms of performance, (inaudible). We've made great progress working with Walgreens. We had a lot of discussions back and forth. We've put together prior authorization processes. We've also looked at the co-pays and I think collectively together those have helped us to increase the ASP in the fourth quarter above the third quarter. But the real problem was in the second quarter, as you know, when we had some very significant issues there. We have now corrected those problems and the third quarter was up -- I believe I said it was up about 40% versus the second quarter. The fourth quarter is up versus third quarter, but I think we have hit approximately the plateau in terms of where we expect those prices for the Walgreens average sales price to go. Paul, do you want to take the next --

    我先回答 Walgreens 的問題,然後把第二部分交給 Paul。關於 Walgreens 的問題,就表現而言,(聽不清)。我們與 Walgreens 合作取得了很大進展。我們來回進行了很多討論。我們建立了事前授權(prior authorization)流程。我們也檢視了自付額(co-pay),我認為這些合在一起,幫助我們在第四季把 ASP 提升到高於第三季。但真正的問題是在第二季,如你所知,當時我們遇到一些非常重大的問題。我們現在已經修正了那些問題,而第三季是上升——我相信我說過相較第二季約上升 40%。第四季相較第三季仍有上升,但我認為就我們預期 Walgreens 平均銷售價格能到的水準而言,已大致達到平台期。Paul,你要接著回答下一個——

  • - CFO

    - CFO

  • Yes, Doug -- if I get this wrong, if it is not responsive to your question I will try again, but let me start. If you look at that key product LOE divestiture impact, what we put there is the impact that you will see on revenue, meaning the growth drag on revenue in 2017 versus 2016 is $785 million. Now, I think the nature of your question is, is the remainder which is the $260 million of this basket of products, how should you think about that?

    是的,Doug——如果我理解錯了、沒有回應到你的問題,我會再試一次,但我先開始說。如果你看那個關鍵產品 LOE 與資產剝離(divestiture)影響,我們放在那裡的是你會在營收上看到的影響,也就是 2017 年相較 2016 年對營收成長的拖累是 7.85 億美元。我想你問題的本質是:剩下的部分,也就是這一籃子產品中的 2.60 億美元,你應該如何看待?

  • That is what led me to, in my discussion around guidance, to talk about the prospects with the diversified segment in 2018 versus 2017 in saying we'd still face some above-average declines in that business. I said 15% to 20% in 2018 versus 2017. And in part that is due to the balance of those, the LOE products, when they go from $1.043 billion in 2016 to circa $260 million in our forecast in our guidance. In 2017, that $260 million doesn't stabilize. That $260 million, based on the timing, it goes away.

    這也是我在談指引時,提到 2018 年相較 2017 年多元化事業(diversified segment)前景的原因:我們仍會面臨該業務一些高於平均的下滑。我說 2018 年相較 2017 年會下滑 15% 到 20%。部分原因在於那些 LOE 產品的剩餘部分:它們從 2016 年的 10.43 億美元,降到我們預測/指引中的約 2.60 億美元。在 2017 年,這 2.60 億美元不會穩定下來。這 2.60 億美元,基於時點因素,會消失。

  • It goes away, I shouldn't say entirely, but it drops pretty dramatically into 2018. So I think both from a revenue and a profitability standpoint, you have got to look at the impact on 2017 and then think about what happens to the remainder of that basket in 2018 and then as it normalizes, I said that business will continue to decline but not nearly as precipitously as you have seen in 2016 versus 2015 or 2017 -- expected 2017 versus 2016. Does that (inaudible), Doug?

    它會消失——我不該說完全消失,但在 2018 年會相當大幅地下滑。所以我認為,無論從營收或獲利角度,你都必須看 2017 年的影響,然後再思考 2018 年那一籃子剩餘部分會發生什麼,接著隨著其正常化,我說該業務仍會持續下滑,但不會像你在 2016 年對比 2015 年,或 2017 年(預期)對比 2016 年所看到的那樣陡峭。這樣有回答到(聽不清),Doug 嗎?

  • - Analyst

    - Analyst

  • Yes, that's very helpful. Thanks a lot, Paul. Then just maybe in terms of the impact of the divestitures on EBITDA contribution, is that $135 million in 2017 guidance? The EBITDA number?

    有的,這非常有幫助。非常感謝,Paul。那再請教一下,關於資產剝離對 EBITDA 貢獻的影響,那 2017 年指引中的 1.35 億美元是指——那個 EBITDA 數字嗎?

  • - CFO

    - CFO

  • It is not. We will update guidance with respect to our divestitures at the time we close the deal. So we will provide information about such things as net proceeds, and use of the proceeds, the impact on revenue for the full year, the impact on interest for the full year and the impact on adjusted EBITDA for the full year. So, when we have certainty about those closures, we will update our guidance accordingly.

    不是。我們會在交易完成交割時,更新與資產剝離相關的指引。因此我們會提供例如淨收益(net proceeds)、收益用途、全年營收影響、全年利息影響,以及全年調整後 EBITDA 影響等資訊。所以,當我們對那些交割有把握時,我們會相應更新我們的指引。

  • Operator

    Operator

  • David Amsellem, Piper Jaffray.

    David Amsellem,Piper Jaffray。

  • - Analyst

    - Analyst

  • I just wanted to ask a couple questions on Xifaxan. So, with the primary care salesforce in place, I just wanted to get your rationale here on the investment and in a primary care salesforce in the context of what is an increasingly competitive environment. With that in mind, how does the presence of a big primary care sales push impact your discussions with payers regarding contracting over the long term? What gives you confidence that you can see net pricing stability over the long term on what will be ostensibly an increasingly primary care focused product? So maybe just give me some color on those dynamics if you can. Thanks.

    我想就 Xifaxan 問幾個問題。所以,在初級照護(primary care)銷售團隊已到位的情況下,我想了解你們在投資初級照護銷售團隊上的理由,尤其是在競爭環境日益激烈的背景下。基於此,大規模的初級照護銷售推進,會如何影響你們與付款方(payers)就長期合約/簽約(contracting)的討論?你們憑什麼有信心,對於一個表面上將愈來愈以初級照護為重點的產品,長期仍能看到淨定價穩定?所以如果可以的話,請就這些動態多提供一些說明。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Sure. This is Joe. The important question for us as we thought about Xifaxan is we believe that many of the patients that are presenting with the IBS-D indication are going to the primary care physician first. Ultimately, we also know many of them will see a gastroenterologist but many of them are seeing the primary care first. We had limited numbers of sales resources in primary care. It was approximately 100 individual sales reps available in primary care. There were many of these primary care physicians we just could not reach with those 100 sales representatives.

    當然。我是 Joe。我們在思考 Xifaxan 時,對我們而言的重要問題是:我們相信,許多以 IBS-D 適應症就診的病人,會先去看初級照護醫師。最終我們也知道,其中很多人會去看腸胃科醫師,但許多人一開始是先看初級照護。我們在初級照護端的銷售資源數量有限。初級照護端大約只有 100 位個別業務代表可用。有許多初級照護醫師,我們用這 100 位業務代表根本無法觸及。

  • We felt that given the longevity of the product, given the opportunity to help improve these patients, we would get out there with an incremental primary care capability. As we mentioned, we hired over 250 individual sales professionals to help join us in delivering the message to primary care. I believe that the actual ability to reach primary care will now be approximately 75% of the prescriptions from primary care for IBS-D we will be able to reach those physicians. So, that is an important part of what we are going to do, but we are going to do more than that.

    我們認為,鑑於該產品的長期性,以及有機會幫助改善這些病患,我們將以增量的基層醫療覆蓋能力走向市場。如同我們提到的,我們已聘用超過250位銷售專業人員,協助我們向基層醫療傳遞訊息。我相信,我們目前實際觸及基層醫療的能力,將可覆蓋約75%的IBS-D基層醫療處方,也就是我們將能觸及開立這些處方的醫師。因此,這是我們將要做的重要一環,但我們要做的不只如此。

  • Again, we are going to do things with the nursing, clinical educators. We're going to continue to talk about our very strong clinical program for Xifaxan that will allow us to really show how this product makes a difference. I know you didn't specifically ask about it, but I will make the mention specifically about Xifaxan and hepatic encephalopathy. We have very strong data that shows it will reduce hospitalizations, which will by definition -- reducing hospitalizations will reduce the overall total cost of healthcare, which is so important to the managed care programs and why we believe we'll be very successful with Xifaxan for the future.

    再次強調,我們也會在護理與臨床教育人員方面採取行動。我們將持續溝通我們針對Xifaxan非常強而有力的臨床計畫,讓我們能真正展現這項產品如何帶來改變。我知道你並未特別問到,但我會特別提及Xifaxan與肝性腦病變。我們有非常強勁的數據顯示它能降低住院率;而依定義,降低住院率將降低整體醫療總成本,這對受管理式醫療計畫非常重要,也正是我們相信Xifaxan未來將非常成功的原因。

  • Operator

    Operator

  • Tim Chiang, BTIG.

    Tim Chiang,BTIG。

  • - Analyst

    - Analyst

  • I have a couple debt questions. Paul, if I look at your capital structure, you have got about, what, a little over $10 billion of senior debt still in the balance sheet. But most of that, I think all of it is actually tied to floating rates. Is there anything you can do to lock in an interest rate in an environment where rates probably are going to go up?

    我有幾個關於債務的問題。Paul,如果我看你們的資本結構,你們的資產負債表上仍有大約、怎麼說,略高於100億美元的優先債務。但其中大部分,我想其實全部都與浮動利率掛鉤。在利率可能會上升的環境下,你們是否能做些什麼來鎖定利率?

  • - CFO

    - CFO

  • Yes, we certainly could. The impact of a 1% increase in the variable rates would impact us by some $100 million of net incremental interest expense based on our current cap structure. So, yes, we've been focusing on mitigating or reducing our exposure of that through the pay down of debt -- pay down of that variable-rate debt including hopefully shortly with the proceeds from asset sales. So, yes, good, absolutely a good thing to look at. We think the question is whether to hedge some of that interest or not. We have elected to not hedge that at this time.

    是的,我們當然可以。以我們目前的資本結構來看,若浮動利率上升1%,將使我們的淨新增利息費用增加約1億美元。所以,是的,我們一直在透過償還債務來降低或減輕這方面的曝險——償還那些浮動利率債務,並希望很快能用資產出售所得來進一步償還。所以,是的,這確實是值得關注、絕對是件好事。我們認為問題在於是否要對部分利息進行避險。我們目前選擇暫時不做避險。

  • - Analyst

    - Analyst

  • Paul, one last question, is that it looks like your principal repayments are going to accelerate in 2018. I know a couple questions highlighted, is it possible that you could refinance some of those principal repayments and extend those maturities out? Paul, you are pretty confident you can do that potentially this year?

    Paul,最後一個問題:看起來你們的本金償還將在2018年加速。我知道有幾個問題提到,是否可能針對其中一些本金償還進行再融資,並把到期日往後延?Paul,你相當有信心今年可能就能做到嗎?

  • - CFO

    - CFO

  • Yes. I think in my prepared remarks, what I said is that we look at the situation in the financial markets and the debt markets every day and with great urgency, you focused on the 2018s, I look at all of the towers of our debt and say it is something that we need to do is to focus on the 2018's, focus on the 2020's. We need to access the capital markets at appropriate times to address in advance those maturities. We are confident that we can do that. But obviously, we have not announced anything on that yet.

    是的。我想在我事先準備的發言中,我說過我們每天都以高度急迫感檢視金融市場與債務市場的情況;你聚焦在2018年到期的部分,而我會看我們所有債務的各個到期梯次,並認為我們需要做的是聚焦2018年到期的、也聚焦2020年到期的。我們需要在適當的時點進入資本市場,以提前處理這些到期事項。我們有信心可以做到。但很明顯地,我們目前尚未就此宣布任何事項。

  • - Analyst

    - Analyst

  • Okay, great. Thanks.

    好的,很棒。謝謝。

  • - Chairman & CEO

    - Chairman & CEO

  • Thank you, everyone, for joining us today and listening to our plans for 2017 and what we are guiding. We look forward to updating you as we go forward with the closing of some of the asset sales and as we move forward with the rest of the year. Thank you again for joining us today. Have a great day, everyone.

    感謝各位今天加入我們並聆聽我們對2017年的計畫以及我們所提供的指引。隨著我們推進部分資產出售的交割,以及在今年剩餘時間的進展,我們期待持續向各位更新。再次感謝各位今天的參與。祝各位有美好的一天。

  • Operator

    Operator

  • This concludes today's conference call. You may now disconnect.

    今天的電話會議到此結束。您現在可以掛線。